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ABSTRACT 
 
The influx of calcium through N-type calcium channels (N-current) affects a myriad of 
neuronal functions. These include the triggering of synaptic release of neurotransmitter, 
adjustment of membrane potential and changes in gene transcription.  N-channels are highly 
modulated proteins, so that N-current is attenuated or potentiated in response to environmental 
changes. In turn, the modulation of N-current has a direct effect on the downstream events, 
making the N-channel a focal point in neural signaling, and its modulation a mechanism for short 
term plasticity.  
The modulation of N-current by M1 muscarinic receptors (M1Rs) is of particular interest 
for several reasons.  The M1R is instrumental in both cognition and memory formation as 
indicated by studies using either pharmacological agents aimed at M1Rs or knockout animals 
lacking M1Rs. Clinically, the M1R is an important target in the treatment of Alzheimer’s disease.   
Thus, like the N-channel, the M1R is an important element of neural signaling.  Moreover, the 
stimulation of M1Rs affects N-current by through signaling pathways which despite being 
studied for decades, are not completely understood.   
For my dissertation I have investigated of M1R signaling on N-current using 
electrophysiological recordings of N-current from freshly dissociated neurons and from HEK 
cells expressing N-channels and M1Rs. Asking how one receptor affects one type of calcium 
channel would seem to be a simple question.  However, the answer has many facets.  Since M1Rs 
have multiple downstream effects and N-channels are highly modulated proteins, stimulation of 
M1Rs initiates several different pathways which modulate N-current. This thesis aims to unravel 
some of the complexities of the interactions of two vital components of neuronal signaling.  Here 
vi 
I present the results of studies elucidating three different actions of M1 signaling of N-current 
modulation.  
The first study I present here examines the effect of N-channel subunit composition on 
modulation of N-current. The stimulation of M1Rs in superior cervical ganglion (SCG) neurons 
elicits a distinct pattern of modulation; inhibiting N-current elicited by strong depolarizations and 
enhancing current elicited by lesser depolarizations.  Thus M1Rs cause two simultaneous 
modulatory effects on N-current; increasing voltage sensitivity and decreasing overall 
conductance.  I found the expression of the N-channel’s β subunit (CaVβ) determines the 
observed effect.  Specifically when the isoform CaVβ2a is expressed M1 stimulation elicits 
enhancement without inhibition. Conversely, when CaVβ1b, CaVβ3, or CaVβ4 are expressed M1 
stimulation elicits inhibition with out enhancement.  These results fit a model in which both the 
enhancing and inhibiting effects of M1 stimulation occur in all channels, but typically inhibition 
dominates. CaVβ2a blocks inhibition unmasking latent enhancement.  Moreover, using mutants 
and chimeras I found palmitoylation of CaVβ2a at the N-terminus plays a key role in blocking 
inhibition.  My findings predict the expression and localization of different CaVβ isoforms would 
dramatically alter modulation of N-current and thus may represent a previously unrecognized 
form of plasticity. 
The inhibition of N-current by M1Rs is controversial.  It has been proposed recently that 
inhibition is directly attributable to the depletion of phosphatidylinositol-4,5-bisphosphate 
[PtdIns(4,5)P2] during M1 stimulation.  However, in our lab, we have found arachidonic acid 
(AA) release, which occurs subsequent to PtdIns(4,5)P2 hydrolysis, is both necessary and 
sufficient to elicit inhibition.  Therefore, in a second study, I tested the effect of CaVβ expression 
on N-current during exogenous AA application and found a pattern of modulation identical to 
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M1R stimulation. Furthermore, I took part in a collaborative project identifying the AA 
producing enzyme, diacylglycerol lipase (DAGL), to be a necessary component of the inhibitory 
pathway elicited by M1Rs.  These findings provide increased evidence for AA release being a 
key factor in the M1R stimulated pathway of inhibition. Moreover, these discoveries identify the 
expression of CaVβ2a and use of specific DAGL inhibitors as a molecular and pharmacological 
strategy to block inhibition of N-current, respectively. These tools allow the dissection of 
downstream effects of M1R stimulation, so that other modulatory effects may be observed.  
The phosphorylation of N-channels by protein kinase C (PKC) blocks inhibition of 
current brought on by G-protein β and γ subunits (Gβγ)  binding directly to the channel. Relief of 
Gβγ inhibition by other means has been identified as a mechanism of short term plasticity. M1Rs 
are known to simulate PKC, but a connection between M1Rs and PKC phosphorylation of N-
channels had not been demonstrated.  I hypothesized that PKC stimulation may be occluded by 
other downstream effects of M1Rs.  Therefore in a third study, I used a pharmacological 
approach on SCG neurons to dissect the PKC activating pathway from the other downstream 
effects of M1 stimulation. I observed modulation of N-current indicating a loss of Gβγ inhibition, 
thus consistent with PKC phosphorylation of channels.  This conclusion reveals another aspect of 
M1 modulation, which can function as a means of short term plasticity. 
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A. Introduction 
In his book Astonishing Hypothesis: The Scientific Search for the Soul, Francis 
Crick contends the human self with all its emotion, memory, consciousness and free will 
is no more than the summed activities of a vast array of nerve cells.  As Dr. Crick puts it, 
Lewis Carroll’s Alice might say, “You’re nothing but a pack of neurons.” (Crick, 1994). 
This proposition is the fundamental working hypothesis of modern neuroscience, 
expanded by Eric Kandel in his book, In Search of Memory: The Emergence of a New 
Science of Mind.  Amongst neuroscientists it is understood that the human psyche is the 
apparent manifestation of physical interactions within the human brain. Therefore, the 
mysteries of what is called self, soul, or mind, may be unraveled as the modern tools of 
science elucidate the various molecular mechanisms of neuronal function (Kandel 2006).  
The molecular mechanisms may be studied as any of a number of neuronal 
transformations; such as changes in gene expression or cell morphology. However, 
antecedent to any lasting plastic changes occurring in neurons are biochemical events 
elicited by surface receptor activation and electrical events conducted by the movement 
of ions.  My thesis describes the how one receptor affects one subtype of voltage-gated 
calcium channel (VGCC); specifically how the activity of N-type calcium channels (N-
channels) is modulated by the activation of M1 muscarinic receptors. Since VGCCs are 
implicated in a variety of neuronal signaling pathways, their modulation can be 
considered a mechanism of short term plasticity (Brody and Yue 2000).  
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B. Voltage-Gated Calcium Channels 
The physiological basis for electric signaling was described over a half a century 
ago when Hodgkin and Huxley (1952) determined that action potentials, the fundamental 
unit of electric signaling, are due to reversible alterations in the ion permeability across 
the plasma membrane.  Their work established the concept of ion selective pores in the 
membrane, and that changes ion flux through sodium and potassium channels conduct 
action potentials.  Soon after, Fatt and Katz (1953) found a current independent of 
sodium or potassium flux and hypothesized the possibility of calcium selective 
permeability.   
We now know VGCCs exist and serve numerous functions within neurons. For 
example, N-type calcium channels are deemed important for triggering neurotransmitter 
release at synaptic terminals (Hirning et al., 1988; Takahashi and Momiyama, 1993; 
Turner et al., 1993), biochemical changes including: enzyme activation (Rittenhouse and 
Zigmond, 1999) and gene transcription (Brosenitsch and Katz, 2001; West et al., 2002). 
N-current also affects calcium activated potassium channels altering the membrane 
potential itself (Wisgirda and Dryer, 1994).  
Calcium’s importance as a signaling molecule starts early in the development of 
life itself. Since calcium readily forms complexes with anionic species, evolutionary 
pressure mandated intracellular calcium levels kept low, otherwise calcium and 
phosphate would precipitate out leaving deposits of hard bone-like solid within cells 
(Jaiswal, 2001; Carafoli, 2002). Cells developed exquisite mechanisms buffering calcium 
to extremely low levels (< 100 nM) making calcium an ideal signaling molecule. In fact, 
calcium influences a huge diversity of functions; everything from the initiation of life at 
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the moment of fertilization to the termination cell life by inducing apoptosis. (for review 
see Berridge, 1998 or Carafoli, 2002). 
VGCCs are multimeric proteins comprising subunits α1, β, α2δ and γ (Fig. 1-1 a).  
The α1 subunit forms the calcium pore and contains the voltage sensor which allows the 
channel to gate during changes in membrane potential. (Fig. 1-1 b; Catterall, 2000; Hille, 
2001). The α1 is surrounded by and modulated by the other ancillary subunits.  VGCCs 
can be broken down into two large groups high voltage activated (HVA) and low voltage 
activated (LVA).  LVA channels respond to relatively low depolarization and comprise 
the T-type channels.  HVA channels are further classified based on biophysical properties 
and sensitivity to pharmacological agents. These are the N-, L- and P/Q- and R- types of 
channels.  L-channels are all sensitive to dihydropyridines (DHP), a class of chemical 
compounds which comprises both L-channel agonists and antagonists. P/Q-channels are 
blocked by the toxin ω-Aga IVA isolated from spider venom, and N-channels are blocked 
by ω-conotoxin GVIA (ω-CTX) (McCleskey et al., 1987; Tsien et al., 1988).  R-current 
was originally used to describe the HVA calcium current that is remaining after 
pharmacological block by DHPs and the two aforementioned toxins. Now R-current more 
commonly refers to a current through a specific channel type closely related to P/Q- and 
N- channels. 
A new nomenclature has been established for VGCCs (Fig 1-2; Ertel et al., 2000).  
The new taxonomy groups channels according to homology.  The CaV1 comprises the 
different L-channels, while the closely related P/Q, N and R- type channels make up the 
CaV2 family. Finally the CaV3 family consists of the known T-type channels. This 
nomenclature was established by a committee of eminent channel scientists studying 
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VGCCs and was meant to supplant the traditional terms which were becoming confusing 
as the list of known α1 subunits expanded.  In his text Ion Channels of Excitable 
Membranes, Bertil Hille has outlined how the conventions are still used. A 
“phenomenological” nomenclature (i.e. HVA vs. LVA or L vs. N) still applies to 
descriptions of currents from cells expressing unknown mixtures of VGCC gene products 
such as dissociated excitable cells.  A “clone” nomenclature (i.e. CaV2.2e) is required for 
to describe experiments using particular gene products or splice variants (Hille 2001). 
The primary structure of VGCC α1 subunit was first determined by Tanabe and 
colleagues in 1987. The analysis of hydrophobic and hydrophilic residues suggested the 
calcium channel had twenty-four membrane spanning a-helices arranged in four repeating 
domains (I-IV) of six alpha helices (S1-S6) (Noda et al 1984).  The four repeating 
domains are often called pseudo-subunits as they are homologous in structure and 
function to the subunits of tetrameric voltage-gated potassium channels.  In each pseudo-
subunit contains at the S4 position is an alpha helix rich in cationic residues.  The S4 is 
known to be important in voltage sensing (Liman et al 1992).  At rest the inside of the 
cell membrane is negatively charged with respect to the extracellular surface, and the 
positive charges of the S4 alpha helices are attracted toward the inside of the cell.  During 
depolarization the charge distribution across the membrane reverses and the positively 
charged portions of the channel are pushed towards the extracellular surface (Durell and 
Guy, 1992).  Between the fifth and sixth helix is a short peptide sequence, the P-loop. 
When the channel is properly folded the P-loops converge to form the pore at the center 
of the channel (MacKinnon and Yellen, 1990) (Fig 1-1 a,b).   
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The pseudo-subunits of the α1 are connected by intracellular loops.  These loops 
together with the amino and carboxy termini of the α1 subunit provide sites for 
modulation by intracellular events. Although many different proteins can interact with α1 
subunits, only three proteins are considered ancillary or auxiliary subunits of the channel. 
These proteins meet the following recommended criteria (from Arikkath and Campbell, 
2003): An ancillary subunit 1) exists in purified channel complexes, 2) directly interacts 
with the α1 subunit, 3) modulates trafficking or biophysical properties of the channel, and 
4) is stably associated with the α1 subunit.   The ancillary subunits β and α2δ are 
particularly important for channel conductivity and expression at the cell surface 
(Catterall, 2000).    
The VGCC β subunit (now commonly referred to as CaVβ) is encoded by four 
distinct genes CaVβ (CaVβ1-4), each gene giving rise to numerous splice variants 
(Dolphin 2003; Birbaumer 1998).  All four genes are expressed in the brain. Each CaVβ is 
made up of five domains (D1-D5). Domains D1, D3, and D5 are highly variable regions. 
While the other two are highly conserved domains, D2 and D4 forming an SH3 domain 
and a guanylate kinase (GK) domain respectively (Fig. 1-1 b).  The two conserved 
domains place CaVβ as a member of the membrane-associated guanylate kinase 
(MAGUK) family (for review see Dolphin, 2003).   All CaVβ subunits bind α1 subunits at 
a highly conserved sequence at the I-II linker termed the alpha interaction domain (AID; 
Pragnell et al., 1994; Fig.1-1 b).  The binding of CaVβ increases surface expression of 
VGCCs by masking an ER retention sequence on the α1 subunit (Bichet et al., 2000).   
The AID corresponding site of the CaVβ subunit was previously identified as the beta 
interaction domain (BID) through mutation and analysis. However, recently, three 
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different labs have obtained crystal structures of CaVβ subunits bound to AID peptides. 
This work published almost simultaneously all show the AID binds CaVβ at a site distinct 
from the BID (Opatowsky et al., 2004; Van Petegem et al., 2004; Chen et al., 2004). 
Since CaVβ subunits contain no transmembrane segments they typically exist completely 
in the cytoplasm.  Some forms can associate with the plasma membrane independent of 
the α1 subunit, most notably the splice variant CaVβ2a which is palmitoylated at two 
cysteine residues near the amino terminus (Chien et al., 1998). 
CaVβ subunits have numerous effects on channel localization and function.  In 
Madin Darby Canine Kidney (MDCK) cells, a polarized epithelial cell line, coexpression 
of Cav2.1 with CaVβ1b and CaVβ4 resulted in transport to the apical membrane, while 
CaVβ2a resulted in transport to the basolateral membrane (Brice and Dolphin, 1999).  
CaVβ subunits have been reported to influence modulation by the fast pathway (Roche et 
al., 1995, Roche and Treistman, 1998).  The findings I will present in the third chapter of 
this thesis describe the influence of CaVβ subunits on N-current modulation via the slow 
pathway.  
Like CaVβ, four known genes exist for α2δ each with multiple splice variants.  The 
α2δ complex associated with a given channel is the product of a single gene which is 
cleaved post-translationally and linked with disulfide bridges.  The δ portion of the 
complex is a transmembrane α-helix which anchors the highly glycosylated α2 portion of 
the complex (Klugbauer et al., 2003).  The α2 seems to be essential for increasing current 
amplitude by a mechanism which is unknown (Caterall, 2000; Arikkath and Campbell, 
2003).  A fourth subunit γ is known to associate with some VGCCs although unlike CaVβ 
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and α2δ, γ subunits do not affect localization of channels to the cell surface (Caterall, 
2000; Arikkath and Campbell, 2003). 
 
C.  N-Channels 
N-currents were first described by members of the Tsien lab using chick dorsal 
root ganglion neurons (Nowycky et al., 1985).  Using whole-cell and single-channel 
recordings they identified previously unknown voltage-gated calcium currents. The 
current discovered by Nowycky and colleagues was given the distinction “N” for neither 
L- nor T-type current; the two previously described VGCCs. These conclusions were 
based on the N-current’s biophysical properties and resistance to DHP (Nowycky et al., 
1985; Fox et al. 1987).  As research in the field continued several types of currents 
similar to N-current which are insensitive to DHP emerged. The discovery of ω-
conotoxin GVIA isolated from snail venom (ω-CTX) presented a pharmacological tool to 
distinguish N-channels (McCleskey et al 1987, Tsien et al 1988, Plummer et al., 1989, 
Boland et al., 1994).  In 1992 an ω-CTX-sensitive VGCC α1 subunit was cloned first 
from rat (Dubel et al., 1992) and then human cells (Williams et al., 1992).  The two 
constructs were 92.8% identical, and had the same architecture for VGCCs described by 
Tanabe and colleagues in 1987 (see Fig 1-1).  It was noted at the time of their discovery 
the expression of N-channels requires the β and α2δ subunits in addition to the α1 
(Williams et al., 1992). 
It was first thought that N-channels expression is restricted to neurons. N–
channels are almost exclusively expressed in neuronal cells although they have been 
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found in cells outside the nervous system including chromaffin cells (Jan et al., 1990) and 
pancreatic beta cells (Sher et al., 1992).   
Recently N-channels have become notable as a therapeutic target for pain 
(Snutch, 2005). ω-CTX and other N-channel specific inhibitors are the basis of 
pharmacological agents being developed to target chronic pain.  The N-channel is also 
the target of a class of compounds referred to as nootropics which can enhance cognition 
in patients with dementia.  It is thought that potentiating N-current enhances release of 
neurotransmitters thus improving neural function (Keren et al 1997, 1999). Specifically, 
N-current enhancing nootropics are thought to increase synaptic release of 
neurotransmitters (Gouliaev et al. 1994; Chorvat et al 1998; Yoshii et al 2000, 2004).   
The N-channel is a highly modulated protein. Biochemical changes within a 
neuron activate signaling pathways altering N-channel activity. In particular, upon 
release, neurotransmitters bind G-protein coupled receptors (GPCRs) and initiate 
signaling pathways, modulating the N-channel’s response to changing membrane 
potential (Elmslie 2003; Hille 1994).  The signaling pathways which modulate N-current 
have been studied intensely for decades. Some signaling pathways remain mysterious, 
despite the concerted efforts of many labs. However, other pathways are well described 
so that now both the necessary components for signaling and the sites on the channel 
which are involved in signaling are known.   
 
D. Muscarinic Receptors 
Muscarinic receptors are seven transmembrane G-protein coupled receptors, 
comprising a family of proteins named encoded by five different genes (M1-M5).   M1 and 
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M2 receptors were determined by members of the Numa lab (Kubo et al, 1986a; 1986b), 
followed by the discovery of sequences for M3, M4, and M5 (Bonner et al.,1987, 1988; 
Peralta et al., 1987).  All five are expressed in the CNS (Levey et al., 1991; Wei et al., 
1994).  In vivo muscarinic receptors are activated by acetylcholine (ACh) (Feldberg and 
Gaddum, 1934). ACh is known as the major ganglionic transmitter in the sympathetic 
nervous system, whereas in the central nervous system (CNS), ACh is crucial for 
cognition, learning and memory (Woolf 1996).  Activation of the M1 muscarinic receptor 
(M1R) is of particular interest, as it is the most prevalent subtype expressed in 
hippocampus and cortex regions of the brain associated with learning and memory 
(Levey et al., 1991; Wei et al., 1994). Severe memory deficits occur in knockout mice 
lacking M1Rs (Anagnostaras et al. 2003).  Clinically, the M1R is a therapeutic target for 
Alzheimer’s disease (AD). In fact, at the present time the majority of drugs approved to 
treat AD act by increasing ACh at M1Rs (Ibach & Haen 2004).  
Muscarinic stimulation affects numerous neural functions including the 
modulation of voltage gated ion channels. In the early 1980s, M-current, a low threshold 
potassium current inhibited by muscarinic stimulation was identified in frog sympathetic 
neurons (Brown and Adams 1980) and rat superior cervical ganglion (SCG) neurons 
(Constanti and Brown 1981).  These findings led to a putative model for how muscarinic 
receptors enhance the excitability of neurons (Brown 1983).  The inhibition of M-current 
was shown to be require stimulation of M1Rs (Marrion et al. 1989; Bernheim et al. 1992) 
acting through Gαq subunits of heterotrimeric GTP binding proteins (Haley et al. 1998).  
After the discovery of M-current, muscarinic stimulation was found to inhibit N-
channels by two distinct pathways a rapid process (less than 1 second) and a slower 
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process (greater than 4 seconds; Bernheim et al., 1991).  The fast-pathway is elicited by 
M2 and M4 receptors and the slow pathway is induced mainly by M1 receptors (Shapiro et 
al 1999). These two pathways are discussed in greater detail in the next sections.  
 
E. The Fast Pathway 
The study of fast pathway inhibition began 28 years ago when Dunlap and 
Fischbach (1978) reported exogenously applied norepinephrine (NE) reduces voltage-
gated calcium current in chick dorsal root ganglion (DRG) neurons.  Subsequently Holz 
and colleagues (1986) implicated G-proteins in the pathway of inhibition when they 
showed inhibition is blocked by pretreating cells with pertussis toxin (PTX) or dialyzing 
cells with GDP-βS.  Soon afterward, Wanke and colleagues (1987) showed muscarnic 
stimulation also inhibits N-current by a PTX-sensitive pathway in rat sympathetic 
neurons. The importance of G-proteins was corroborated by experiments in which 
dialysis of GTP-γS mimicked the effect of neurotransmitter of calcium currents in DRG 
neurons; first in rat (Dolphin and Scott, 1987) then in chick (Marchetti and Robello, 
1989). Moreover, inhibition of calcium currents in rat sympathetic neurons by either ACh 
or NE becomes irreversible when cells are dialyzed with GTP-γS (Song et al., 1989).   
Originally it was thought that neurotransmitters inhibit current by somehow 
reducing the number of functional channels in the cell (Dunlap and Fischbach, 1978). An 
alternative model was proposed by Bruce Bean (1989) in which transmitters inhibit N-
current by changing the voltage-dependence of channels. Bean noticed that 
neurotransmitters do not inhibit N-current equally across all test potentials.  At low to 
moderate test potentials (-40 mV to +30 mV) neurotransmitters reduce the probability 
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that channels will open upon depolarization. At higher test potentials the 
neurotransmitters elicit little effect.  Bean proposed channels exist in either a “willing” or 
“reluctant” state, and the activation of certain GPCRs pushes the bulk of channels from 
the willing to reluctant state.  At low to moderate test potentials, the current elicited from 
channels in the reluctant state increases over a prolonged (100 msec) depolarization. 
Bean reasoned that slowly activating currents during prolonged depolarizations were due 
to channels moving from the reluctant to willing state.  
Bean’s model fit well with a previously proposed hypothesis that GPCR elicited 
inhibition might be relieved by a series of depolarizations (Marchetti et al 1986).  The 
voltage-dependent model was advanced when Keith Elmslie and colleagues, using frog 
sympathetic neurons, found that a large transient depolarization reverses the inhibition 
elicited by a neurotransmitter or internally dialyzed GTP-γS (Elmslie et al., 1990).  
Elmslie’s prepulse experiments confirmed the notion that the two states willing and 
reluctant could be separated rapidly and easily by voltage. Moreover, Elmslie’s protocol 
established an elegant method to observe the proportion of channels in the willing or 
reluctant state under specific conditions of modulation.  The relief of inhibition was 
termed facilitation and eventually, it was shown that repetitive physiological 
depolarizations transiently relieve inhibition in a similar manner (Brody et al., 1997; 
Artim and Meriney 2000).  
Having identified a role for specific G-proteins and a biophysical mechanism for 
inhibition the next challenge for the field was to work out other steps in the pathway.  
Lopez and Brown (1991) discovered the re-inhibition of N-currents after prepulse 
facilitation is dependent on the concentration of activated G protein and hypothesized that 
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inhibition results from G-proteins bound directly to channels. Their hypothesis was 
supported by the co-precipitation of both Gα and Gβγ subunits bound directly to N-
channels (McEnery et al 1994).   
To determine whether Gα, Gβγ or both subunits were necessary for modulation of 
CaV2 channels, N- currents were recorded from SCG neurons injected with mRNAs for 
G-protein subunits (Ikeda, 1996) and P/Q- currents were recorded from tsA cells 
overexpressing G-protein subunits (Herlitze et al., 1996).  In both cases overexpression of 
Gβγ mimicked the voltage-dependent inhibition normally elicited by neurotransmitters or 
internally dialyzed GTP-γS.  Conversely, neither transfection of a constitutively active 
Gα subunit in SCG neurons, nor a range of Gα subunit concentrations in tsA cells elicits 
inhibition of CaV2 channels (Ikeda, 1996; Herlitze et al., 1996).  These data indicated the 
reluctant state of CaV2 reflects the direct binding of Gβγ subunits to CaV2 subunits.  
Moreover, they strongly suggested prepulse facilitation works by dislodging Gβγ 
subunits from CaV2. 
Having established the mechanism for current inhibition, many labs tried to 
pinpoint the site of Gβγ binding on CaV2 subunits.  The site of Gβγ was sought using 
mutated CaV2 subunits and chimerae of CaV2 and CaV1 sequences since L-channels are 
G-protein insensitive. Three regions of CaV2 emerged as important for Gβγ interaction; 
the intracellular loop between pseudo-subunits I and II (I-II linker; DeWaard et al., 1997; 
Zamponi et al 1997), the carboxy tail (Qin et al 1997), and the amino terminus (Zhang et 
al., 1996; Page et al., 1998; Canti et al., 1999).  The most recent intensive work in this 
area on N-channels indicated that inhibition arises from an interaction between the CaV2 
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amino terminus and the I-II loop (Agler et al., 2005), however the specifics of this 
interaction are not well described. 
 
F. Block of Gβγ Modulation by Protein Kinase C 
At the same time the mechanism for inhibition of calcium currents by GPCRs was 
being worked out, it was shown that phorbol esters enhance calcium currents in 
sympathetic neurons (Yang and Tsien, 1993; Swartz et al 1993, Zhu and Ikeda 1994).  
The two observations intersected when it was shown that pretreatment of neurons with 
phorbol esters blocked inhibition by neurotransmitters (Swartz et al., 1993; Swartz, 
1993).  These data implicated protein kinase C (PKC) as an agent for control of the fast 
pathway. Since phorbol esters can activate enzymes other than PKC, the experiments 
were repeated using intracellular dialysis of a PKC inhibiting peptide. The blocking 
peptide, but not the “scrambled” peptide control, attenuates the block of inhibition by 
phorbol esters (Swartz, 1993). Moreover the actions of phorbol esters were equivalent to 
prepulse facilitation (Fig 1-4 a, b).  Using phorbol esters, GTP-γS, and Elmslie’s voltage 
protocol, Barrett and Rittenhouse (2000) set up an array of experiments which extended 
the model still further; showing that as phosphorylation blocks G-protein binding, G-
protein binding interferes with phosphorylation.  They expanded Bean’s designations of 
channels to include “willing and available” to describe those channels which were neither 
inhibited by Gβγ binding nor phosphorylated by PKC (Fig 1-5 b). 
The work by Swartz suggested a direct antagonism between PKC activity and G-
protein binding.  In 1997 Gerard Zamponi and colleagues identified what they termed a 
center of “crosstalk” at the I-II linker, the intracellular loop of CaV2 connecting pseudo-
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subunits I and II. The I-II linker of CaV2.2 has several consensus sites for 
phosphorylation by PKC (Dubel et al 1992), and, as noted above, the I-II linker of CaV2.2 
was implicated as an important site for Gβγ binding. The I-II linker was shown to bind 
Gβγ subunits in vivo experiments (De Waard et al., 1997, Zamponi et al, 1997) and in a 
yeast-two hybrid assay (Garcia et al., 1998).  Peptides consisting of residues from this 
region prevented inhibition when dialyzed into cells, presumably by competitively 
binding, thus effectively sequestering Gβγ subunits (Herlitze et al., 1997; Zamponi et al., 
1997).  However, when I-II linker peptides were phosphorylated in vitro they lost the 
capacity to block inhibition (Zamponi et al., 1997).  These data led to the conclusion that 
phosphorylation of the I-II linker prevents the direct binding of Gβγ subunits thus 
blocking transition to the “reluctant” state. 
To ascertain the specific site of phosphorylation that is important for cross-talk a 
series of CaV2.2 subunit mutations were produced, expressed in HEK cells, and examined 
for resistance to modulation (Hamid et al., 1999).  There are four possible PKC 
phosphorylation sites on the I-II linker (Fig 1-4 a).  A series of experiments in which the 
possible PKC sites were mutated to alanine (to show loss of phosphorylation) or 
glutamate (to approximate constitutive phosphorylation) proved Thr422 is the most 
essential phosphorylation site to block inhibition by Gβγ subunits (Hamid et al., 1999).   
Although the cross-talk between PKC and G-protein inhibition provides a 
reasonable and attractive model for modulation of CaV2.2, the in vitro activators of PKC 
to block fast pathway inhibition have proven to be elusive.  PKC is typically activated by 
diacylglycerol (DAG) which is released by activation of phospholipase.  A number of 
GPCRs are known to activate phospholipses, among them the M1Rs activation of 
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phospholipase C-β (PLC-β).  In the fifth chapter of this thesis I will describe experiments 
I’ve conducted to examine a role for M1Rs in crosstalk with the fast pathway.  The 
observation of PKC activation by M1Rs may be normally occluded by other signaling 
pathways which occur downstream of M1R stimulation, most notably the so-called slow 
pathway which is described in the next section. 
 
G. The slow pathway  
 
In addition to the previously described fast pathway, muscarinic stimulation 
inhibits whole cell calcium currents in sympathetic neurons through M1Rs by a pathway 
known as the slow pathway. The two pathways can be differentiated by several features 
(Fig 1-3).  Unlike the fast pathway, the slow pathway is both PTX-insensitive and voltage 
insensitive (Wanke et al., 1987; Beech et al., 1992) Also, the slow pathway is disrupted 
by high concentrations (20 mM) of the calcium chelator bis(O-aminophenoxy)ethane-
N,N,N',N'-tetraacetic acid (BAPTA; Beech et al., 1991; Mathie et al., 1992). Finally, in 
single-channel recordings, channels isolated by the patch pipette are still affected by the 
agonist indicating there is at least one diffusible second messenger in the pathway 
(Bernheim et al 1991; for review see Hille 1994). 
The discovery of M1R mediated inhibition of N-current followed the discovery of 
M1R mediated inhibition of a voltage-gated potassium current (M-current; Brown and 
Adams, 1980). The two types of inhibition share several common characteristics 
including the concentration of muscarinic agonist required to induce inhibition and the 
time frame in which inhibition occurs.  Therefore, it was postulated that the two types of 
inhibition may be caused by a similar mechanism.  That is, hypothetically, one diffusible 
second messenger or set of second messengers released during M1 stimulation might be 
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responsible for both types of inhibition (Hille 1994; Delmas et al 2005; Delmas and 
Brown, 2005).  Of course, a similarity in function does not prove a conservation of 
mechanism, and the fact that the same concentration of agonists elicits both effects may 
have more to do with the agonist’s affinity for the receptor than a parallel response of 
downstream effects.  Still, the resemblance of modulation by two voltage-gated channels 
by stimulation the one receptor merits constant comparison between the two fields of 
research.    
Even though inhibition of both N- and M- current by muscarinic agonists has 
been the subject of study for many labs the identification of the diffusible second 
messenger(s) has been elusive. Early experiments ruled out a role for cAMP, cGMP, 
nitric oxide and protein kinases in the slow pathway (reviewed by Hille, 1994).  The 
predominant effect of M1R stimulation is the activation of phospholipase C.  The 
necessity for PLC activation in both M- and N-current modulation has been well 
documented (reviewed in Suh and Hille 2005; Delmas and Brown 2005). Amongst the 
different downstream effects of M1Rs through PLC two have emerged as possible key 
mechanisms for N-current inhibition.  They are: 1) the breakdown of 
phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] and its consequent dissociation 
from CaV2 subunits (Wu et al Gamper et al 2002; Delmas et al 2005), and 2) the release 
of arachidonic acid (AA) which occurs subsequent to PtdIns(4,5)P2 hydrolysis and 
inhibits N-current either directly or indirectly (Fig. 1-6; Liu et al 2006; Liu and 
Rittenhouse 2003).  
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H. Modulation of N-current by PtdIns(4,5)P2 
PtdIns(4,5)P2 constitutes less than 1% of the membrane phospholipids yet it is the 
component of a vast array of signaling paradigms (Czech 2000). PtdIns(4,5)P2 is known 
classically for the effects of its breakdown products PKC activation by DAG and internal 
calcium release from IP3 receptors activated by Ins(1,4,5)P3.  However, there is a new 
field of PtdIns(4,5)P2 study which focuses on direct binding of PtdIns(4,5)P2 and 
subsequent activation of proteins  The low concentration of PtdIns(4,5)P2 allows for  its 
rapid depletion when PLC is stimulated.  In neuroblastoma cells muscarinic stimulation 
reduces PtdIns(4,5)P2 by 75% within 60 seconds (Willars et al 1998). The study of 
PtdIns(4,5)P2 mediated effects received a lift from advent of green fluorescent protein 
(GFP)-PLCδ-pleckstin-homology (PH) domain binds PtdIns(4,5)P2 at cell surfaces and 
thus allows the real time comparison of PtdIns(4,5)P2 breakdown with downstream 
effects (Czech 2000).  
The implication of PtdIns(4,5)P2 as the signaling molecule for CaV2 coincides 
with work connecting PtdIns(4,5)P2 with inhibition M-current and follows seminal work 
indicating PtdIns(4,5)P2 directly modulates ATP sensitive potassium channels 
(Hilgemann and Ball, 1996).  For M-current the time course of inhibition and recovery 
mirrors the breakdown and resynthesis of PtdIns(4,5)P2.  In whole-cell recordings and 
excised patches PtdIns(4,5)P2 activates channels and attenuates rundown of current 
(Zhang et al., 2003; Ford et al., 2004).  
The evidence for PtdIns(4,5)P2 having a role in CaV2 modulation comes mainly 
from two studies. First, dual opposing modulatory effects of PtdIns(4,5)P2 were reported 
for CaV2.1 (Wu et al 2002). In large excised patches from frog oocytes channel activity 
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ran down  Channel activity was restored by  puffing PtdIns(4,5)P2 Channel activity was 
decreased by sequestering PtdIns(4,5)P2 with cationic peptides or antibodies specific for 
PtdIns(4,5)P2.  Wu and colleagues postulated PtdIns(4,5)P2 binds to the “S” (for 
stabilization) domain of the channel thus stabilizing current. Surprisingly the authors 
found PtdIns(4,5)P2 also caused a shift in activation potential.  The authors compared the 
shift in voltage sensitivity to Bruce Bean’s willing and reluctant model.  They postulated 
a second binding site for PtdIns(4,5)P2 on the channel, the “R” (for reluctant) domain. 
PtdIns(4,5)P2 binding to the R domain hypothetically shifts the channel to the reluctant 
mode, requiring stronger depolarizations.  
The second study was done on native N-channels in SCG neurons (Gamper et al 
2004). The authors of this study also found PtdIns(4,5)P2 attenuates rundown.  
PtdIns(4,5)P2 dialyzed into cells during whole-cell recordings reduces inhibition elicited 
by the muscarinic agonist oxotremorine methiodone (oxo-M).  Also, inhibition by oxo-M 
becomes irreversible when resynthesis of PtdIns(4,5)P2 is blocked by wortmannin. 
These data taken together have been declared clear evidence that CaV2 channels 
require PtdIns(4,5)P2 for activation (Suh and Hille, 2005; Delmas and Brown, 2005). 
 
I. Modulation of N-current by AA 
The requirement for PtdIns(4,5)P2 hydrolysis in the slow pathway is clear.  
However, previously Liwang Liu in Ann Rittenhouse’s lab determined modulation of N-
current by M1Rs requires events downstream of PtdIns(4,5)P2 hydrolysis (Liu et al 2004).  
In superior cervical ganglion (SCG) neurons M1R stimulation and arachidonic acid (AA) 
elicit the same distinct pattern of modulation (Liu et al. 2001; Liu et al. 2003); inhibiting 
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whole-cell N-current at positive test potentials and enhancing N-current at negative test 
potentials (Fig 1-7).  A similar pattern of modulation emerges when AA or its 
corresponding amide anandamide is applied to VGCCs. For example, whole-cell currents 
from adult rat SCG neurons are enhanced at negative potentials and inhibited at positive 
potentials by anandamide (Guo and Ikeda 2004). Although enhancement was not 
observed in T-type channels, AA also simultaneously shifts activation towards negative 
potentials and increases steady state inactivation (Talavera et al 2004).   
M1R stimulation releases AA (Tence et al 1994; Strosznajder & Samochocki 
1992) suggesting a role in the slow pathway.  Consistent with this hypothesis, reduction 
of AA levels either by the PLA2 antagonist oleyloxyethyl phosphocholine (OPC) or by 
absorption of AA with a fatty acid free bovine serum albumin (BSA) minimizes both 
enhancement and inhibition of N-current (Liu & Rittenhouse 2003; Liu et al. 2004).  
More recently Liwang Liu has examined the role of AA production in inhibition of L-
current.  He has found the slow pathway is attenuated by PLA2 specific antibodies 
dialyzed internally and in recordings from neurons harvested from PLA2-/- knockout mice 
(Liu et al., 2006).  
In the fourth chapter of this thesis I will describe a collaborative project between 
Liwang and myself demonstrating the necessity of another AA producing enzyme, DAG 
lipase, in slow pathway inhibition. 
 
J. A controversy for PtdIns(4,5)P2 and AA 
The assumption that PtdIns(4,5)P2 binds directly to CaV2 channels, thus 
stabilizing its current has been proposed and acknowledged by several labs (Delmas et al 
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2005, Suh and Hille 2005).  Still, at present, no binding site for PtdIns(4,5)P2 on any 
VGCC has been determined.  However, there is increasing evidence that M-current and 
CaV currents are modulated by divergent pathways.  For example it was recently reported 
that palmitoylated cationic peptides designed to sequester PtdIns(4,5)P2 blocked 
inhibition of M- but not N- current (Robbins et al 2006).  These data would agree with 
our finding that AA production is necessary for inhibition of N- and L- but not M-current 
(Liu et al 2006; Chapter IV of this thesis).    
It is possible the PtdIns(4,5)P2 model and AA model can co-exist. A model in 
which PtdIns(4,5)P2 and AA act in opposition on the same pathway has been reported in 
potassium channels (Oliver et al 2004). Fast inactivation of certain Kv channels is 
blocked by PtdIns(4,5)P2 but enhanced by AA.  The authors of this study reported a 
PtdIns(4,5)P2 binding site at the N-terminus of the Kv channel and postulated AA acts 
through an allosteric modification of the channel.   
Here, I have described two modulatory effects of PtdIns(4,5)P2 on CaV2 and two 
modulatory effects of AA on CaV2.  In both types of modulations PtdIns(4,5)P2 and AA 
act in opposite directions. PtdIns(4,5)P2 sustains CaV2 currents while AA inhibits 
currents.  PtdIns(4,5)P2 causes an activation shift to positive potentials while AA causes 
an activation shift to negative potentials. Thus, as for the Kv channel PtdIns(4,5)P2 and 
AA may act on the same pathways but in opposite directions.  Our data indicate the block 
of AA production completely eliminates inhibition, also exogenous AA elicits inhibition, 
so AA is necessary and sufficient to cause inhibition.  It is possible under normal 
physiological conditions as PtdIns(4,5)P2 depletion and AA formation occur 
simultaneously, VGCCs are sensitive to both consequences of M1R stimulation. 
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Moreover, it is possible under experimental conditions application of either PtdIns(4,5)P2 
or AA could seem to function independently if either was used at high enough 
concentrations.  
In summary, the modulation of N-current by M1Rs is highly complex.  M1Rs 
initiate multiple signaling cascades several of which may converge on the N-channel.  
The remainder of this thesis will be descriptions of how those signaling cascades may be 
teased apart for a better understanding of how M1Rs affect N-current. 
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Figure 1-1. Voltage-gated Calcium Channels (VGCC).  (a) Voltage gated calcium 
channels are multimeric complexes made up of a large (170- 250 kDa) α1 subunit, which 
is surrounded by and modulated by the ancillary subunits β and α2δ.  A fourth subunit γ 
which may be associated with VGCCs is not shown.  VGCCs span the plasma membrane 
and allow the permeation of calcium into the cell during periods of depolarization. (b) 
Shown here is the secondary structure of VGCC subunits. The α1 subunit 24 membrane 
spanning α-helices are grouped into four homologous pseudo-subunits (I-IV), each 
containing six membrane-spanning α-helices.  Of note is the fourth α-helix of each 
pseudo-subunit (S4) which contains a concentration of cationic residues which are crucial 
for sensing changes in membrane potential. Also of note are the fifth and sixth α-helices 
(S5 and S6) and the short loop of peptide between the two (the P-loop). The P-loop forms 
the structure of the pore and thus determines the selection of ion by the channel.  
Between the pseudo-subunits are large intracellular loops.  These loops in conjunction 
with the amino and carboxy termini provide sites for biochemical interactions with 
intracellular proteins. β subunits are completely cytoplasmic and bind the α1 subunit at a 
sequence termed the AID located within the I-II linker. β subunits each have a SH3 
domain and a guanylate kinase (GK) domain. The AID is bound at the GK of the β 
subunit. The α2δ subunit is the result of one gene which is spliced post-translationally and 
secured with disulfide bridges.  The δ portion of the subunit forms a single membrane 
spanning α-helix, anchoring the α2δ subunit in the membrane.  The α2 portion of the 
subunit is highly glycosylated and completely extracellular. The figures shown were 
created from a compilation reports cited in the text.  
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Figure 1-2. Subfamilies of Voltage-Gated Calcium Channels (VGCCs). Presented is a 
dendogram depicting taxonomy of voltage-gated calcium channels as determined by 
sequence homology.  Modern nomenclature categorizes VGCC genes in three large 
subfamilies; CaV1, CaV2, and CaV3. The high voltage activated channels (HVA) 
comprises CaV1 and CaV2, which encompass the L-, P/Q, N- and “R”- type channels as 
labeled on the horizontal connectors of the dendogram.  These were first differentiated by 
biophysical properties, and later by pharmacology:  L-channels being sensitive to 
dihydropyridines, P/Q-channels sensitive to the toxin ω-Aga IVA isolated from spider 
venom, and N-channels sensitive to ω-conotoxin GVIA isolated from snail venom.  “R”- 
channels were named for the HVA channels not sensitive to the aforementioned 
pharmacological agents, however more recently the designation “R” has come to be used 
more specifically and correspond to the CaV2.3 channel as shown.  The low voltage 
activated channels (LVA) comprise the T-type channels. The matching percentage of 
amino acid sequences was determined by comparing the homologous regions of the 
different channel sequences (the transmembrane segments and P-loops; see Fig 1-2), 
about 350 amino, acids using the CLUSTAL algorithm (see Ertel et al 2000).  Shown at 
far right, in parentheses, are the previously used conventional designations for VGCC 
genes.  The classification was superseded by the classification shown in the dendogram 
which reflects homology between channel types (see Ertel et al 2000; also Hille 2001) 
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Figure 1-3. Pathways of Muscarinic inhibition of N-type Calcium Channels. Muscarinic 
stimulation of SCG neurons elicits modulation of N-channels through two distinct 
pathways as shown.  The fast pathway illustrated at left was formerly called the 
membrane delimited pathway since channels isolated by a patch pipette are not affected 
by ligands for receptors outside the pipette.  The muscarinic receptors which elicit fast 
pathway inhibition are the M2 and M4 receptors. It is known now known that fast 
pathway inhibition results from direct binding of Gβγ subunits to CaV2.2.  See text for 
details.  The slow pathway illustrated at right is elicited by M1 muscarinic receptors in 
SCG neurons.  M1 simulation will affect channels isolated from muscarinic agonists by 
the patch pipette and thus the slow pathway is known to involve at least one diffusible 
second messenger.  Slow pathway inhibition requires PtdIns(4,5)P2 breakdown by the 
enzyme phospholipase C.  However, whether or not events subsequent to PtdIns(4,5)P2 
hydrolysis are essential for N-current modulation remains controversial. Each of the two 
pathways may be induced by ligands other than muscarinic agonists.  As listed at the 
bottom of the figure, the two pathways are distinguished by several characteristics 
including sensitivity to voltage protocols, the Ca2+ chelator BAPTA, and PTX toxin. 
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Figure 1-4. Crosstalk for Gβγ and PKC. (a) Stimulation of GCPRs actvates G-proteins 
direct binding of Gβγ to CaV2.2, inhibiting N-current.  Activation of PKC blocks 
inhibition. (b) Intracellular loops provide sites of interaction with intracellular 
mechanisms. Gβγ binds CaV2.2 at several sites including N-terminus, I-II linker and C-
terminus.  Mutational analysis of PKC consensus sites at the I-II linker has demonstrated 
phosphorylation of the I–II linker blocks Gβγ binding.  Note: The site of crosstalk for 
PKC and Gβγ and the binding site for calcium channel β-subunit (CaVβ) are on the I-II 
linker of the α1subunit (Zamponi et al., 1997; Pragnell et al., 1994; Hamid et al., 1999).   
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Figure 1-5. Willing, Reluctant and Available Modes of Channel Activity (a) voltage 
protocol established by Keith Elmslie (Elmslie et al 1990) relieves tonic inhibition of N-
current. A strong prepulse to +80 mV drives channel from “reluctant” to “willing” state 
evidently by dislodging Gβγ from CaV2.2.  Prepulse increases amplitude of current and 
changes kinetics  (b) whole cell recordings from cells exposed to PMA activates PKC and 
results in loss of prepulse facilitation (c) Model proposed by Barrett and Rittenhouse 
(2000) in which channels phosphorylated and dephosphorylated channels both behave as 
“willing”.  Only dephosphorylated channels are available for G-protein modulation.  
Moreover G-protein binding limits availability of PKC site. 
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Figure 1-6. The PtdIns(4,5)P2 cycle.  Phosphorylation of phosphoinositide (PI) at the 3,4, 
and 5 positions on the inositol ring generates mono-, bis-, and trisphosphate derivatives 
with different signaling possibilities.  This figure depicts signaling pathways affected by 
PtdIns(4,5)P2 which may directly or indirectly modulate N-current.  The consecutive 
activity of phosphoinositide-4 kinase (PI4K) and phosphoinositide 5-kinase (PIP5K) 
produces phosphatidylinositol-4-phosphate [PtdIns(4)P] and phosphatidylinositol-4,5-
bisphosphate [PtdIns(4,5)P2], respectively.  PtdIns(4,5)P2 may be dephosphorylated by 5-
phosphatase (PIP2 5-Pase) to PtdIns(4)P, which in turn can be dephosphorylated to PI. 
Stimulation of certain G-protein-coupled receptors (GPCRs) activates phospholipase C 
(PLC). In turn, PLC cleaves PtdIns(4,5)P2, producing the second messengers inositol 
(1,4,5)-trisphosphate [Ins(1,4,5)P3] and diacylglycerol (DAG). Ins(1,4,5)P3 releases Ca2+ 
from intracellular stores through activation of the Ins(1,4,5)P3 receptor (IP3R). Free 
Ins(1,4,5)P3 is quickly dephosphorylated by specialized phosphatases that remove 
specific phosphates to generate inositol.  DAG can activate protein kinase C (PKC) either 
by itself or in conjunction with Ca2+. Alternatively, DAG may be recycled into 
phosphoinositide through DAG kinase mediated phosphorylation to phosphatidic acid 
(PA). After which PA combines with inositol to reform PI. Finally, DAG can be 
hydrolyzed by DAG lipases to release arachidonic acid (AA).  
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Figure 1-7. AA and Oxo-M Elicit Eame Distinct Pattern of Current Modulation. Here are 
shown current relations voltage (I-V plots) for averaged whole-cell recordings from SCG 
neurons as shown for either oxo-M or AA whole-cell current is enhanced at negative 
potentials but inhibited at positive potentials (a) averaged paired recordings in absence an 
presence of 5 µM AA. (b) averaged paired recordings in absence an presence of 10 µM 
oxo-M. (from Liu and Rittenhouse 2003)  
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A.Transfection of HEK M1 cells 
Human embryonic kidney (HEK) cells with a stably transfected M1R [HEK-M1, a 
generous gift of Emily Liman (University of Southern California, Pasadena, CA), 
originally transfected by Peralta et al., (see Peralta et al., 1988)] were transferred into 12-
well plates for transfection. Recombinant cells at 50-80% confluence were transfected for 
1 hour with CaV2.2e, α2δ-1, and various CaVβs at a 1:1:1 molar ratio along with enhanced 
green fluorescent protein (eGFP) at ~10% of the total DNA, using Lipofectamine and 
PLUS reagent [Invitrogen (Carlsbad, CA)] per the manufacturer’s instructions.  500-
1000ng total DNA were transfected per well.  24-48 hours post-transfection cells were 
replated on poly-L-lysine coated coverslips and allowed to settle for at least 1-1.5 hours 
prior to recording.  tsA 201 cells stably transfected with CaV2.2e, α2δ-1, and CaVβ3 were 
generously provided by Diane Lipscombe (Brown University, Providence, RI). Cells 
were transfected with 500-1000 ng per well of the M1R (#J04192; generous gift of Neil 
Nathanson) along with along with eGFP at 10% of the total DNA and processed for 
whole cell current recording as above. 
The β subunits used were CaVβ1b (GenBank #X61394), CaVβ2a(#M80545) and 
CaVβ4 (#L02315)  were provided by Edward Perez-Reyes (University of Virginia, 
Charlottesville, VA); CaV2.2e (# AF055477), α2δ-1 (#AF286488), and  CaVβ3 (#M88751) 
provided by Diane Lipscombe (Brown University, Providence, RI); the CaVβ2a(C3,4S) 
mutant generously provided by Anne Cahill (University of Chicago, Chicago, IL), 
CaVβ2aβ3 chimera and CaVβ2aβ1b chimera generously provided by Robert Ten Eick 
(Northwestern University, Chicago, IL) were generated by Marlene Hosey’s lab (see 
Chien et al 1998). Recordings from untransfected cells yielded whole cell currents of 9.0 
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+/- 1.3 pA in 20 mM Ba (data provided by Mandy Roberts-Crowley).  To avoid spurious 
results from endogenous currents, any transfected cells cells having less than 150 pA 
were discarded.  
 
B. Preparation and culture of SCG neurons 
Following decapitation, the superior cervical ganglia (SCG) were removed from 
1- to 4-day-old Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA), and 
neurons were dissociated by trituration through a 22-gauge, 1.5-in. needle. Following 
dissociation, cells were plated on poly-L-lysine-coated glass coverslips in 35-mm culture 
dishes and incubated at least 2 hours before recording. Cells were maintained in 5% CO2 
at 37°C, in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 7.5% 
fetal bovine serum, 7.5% calf serum, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, 4 
mM L-glutamine and 0.2 µg/ml nerve growth factor (Bioproducts for Science, 
Indianapolis IL).  Cells were used within 14 h of preparation.  
 
C. Electrophysiology 
All currents were recorded at room temperature (20-24°C) using the whole-cell 
configuration of a Dagan 3900a patch-clamp amplifier (Dagan Instruments Inc., 
Minneapolis, MN). Currents were filtered at 5 kHz using the amplifier's four-pole low-
pass Bessel filter, then digitized at 20 kHz with a CED micro1401 interface (Cambridge 
Electronic Design, Cambridge, U.K.). Data were collected using the CED Patch software 
suite, version 6.3 (Cambridge Electronic Design) and stored on a personal computer.  
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Ba2+ currents were obtained using standard whole-cell techniques.  Cells were placed in a 
glass-bottomed dish holding approximately 0.75 ml of bath solution. Patch electrodes 
were filled with the internal solution containing (in mM): 135 Cs-Asp, 10 HEPES, 0.1 
1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), 5 MgCl2, 4 ATP, 
0.4 GTP, adjusted to pH 7.5 with CsOH and brought into contact with cells selected for 
roundness. Cells were patched in Tyrode’s solution containing (in mM) 145 NaCl, 5.4 
KCl, 10 HEPES, pH adjusted to 7.5 with NaOH.   After rupturing the cell membrane, the 
bath solution was exchanged by a gravity fed perfusion system flowing at approximately 
8 ml/min. The external solution contained (in mM): 125 NMG-Aspartate, 10 HEPES, 
0.005 Tetrodatoxin (TTX) 20 Barium Acetate, pH adjusted to 7.5 with CsOH. For 
measurements in which concentration was lowered from 20 to 5 mM the external solution 
as diluted with a solution containing (in mM) 135 NMG –Aspartate, and 10 HEPES.  
TTX was not used when measuring currents from recombinant cells. For all Ba2+ 
recordings cells were held at -90 mV and given a 100 msec depolarization to the test 
potential indicated in the results section of each chapter.  For prepulse experiments a 100 
ms depolarization to +80 mV was applied, cells returned to -90 mV holding potential 
briefly (5 msec) and then given a 100 msec depolarization to +10 mV (protocol based on 
Emslie et al, 1990; see Fig 1-5 a) Prior to analysis, capacitive and leak currents were 
subtracted using a scaled-up current elicited with a test pulse to -100 mV.  Pipette 
resistance ranged from 2.5 to 5 MΩ. 
M-currents were also measured using standard whole-cell techniques. The internal 
solution contained (in mM): 175 KCl, 5 MgCl2, 5 HEPES, 0.1 BAPTA 4 ATP, 0.4 GTP, 
adjusted to pH 7.5 with KOH. The external solution contained (in mM): 160 NaCl, 2.5 
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KCl, 2 CaCl2·6H2O, 1 MgCl2, 11 HEPES, 8 glucose, 0.005 TTX. pH adjusted to 7.5 with 
NaOH.  Cells were patched and membranes were ruptured in external solution. For 
measurement of M-current cells were held at -20 mV and hyperpolarized to -60 mV for 
500 msec, then repolarized to -20 mV.  For time courses current was measured 400 msec 
after repolarization.   M-current traces were not leak subtracted. Pipette resistance ranged 
from 2.5 to 5 MΩ 
 
D. Pharmacology 
Oxotremorine methiodide, [oxo-M; Tocris Biosciences Inc (Bristol, UK)], 
norepiepherne –(+)-bitartrate [NE; Calbiochem La Jolla, CA), bovine serum albumin 
fraction V, heat shock, fatty acid ultra-free [BSA; Roche Dagnostics (Indianapolis IN)] 
methoctramine (METH), bisindolylmaleimide HCl (BLM; Calbiochem), or protein 
kinase Cε translocator inhibitor peptide (PKCε-TIP) were prepared as stock solutions in 
double-distilled water and then diluted 1,000 times with bath solution.  Arachidonic acid 
(AA; Nu Chek Prep, Elysian, MN) FPL 64176 (2,5-dimethyl-4-[2-
(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylic acid methylester) [FPL; Research 
Biomedicals (Natick, MA)], nimodipine [NMN; Miles (New Haven, CT)], RHC 80267 
[1,6-di(O-(carbamoyl)cyclohexanone oxime)hexane] (RHC, Biomol (Plymouth Meeting, 
PA)] or oleyloxyethyl-phosphorylcholine (OPC; Calbiochem), were prepared as stock 
solutions made up in 100% ethanol and diluted 1,000 times with bath solution. Aliquots 
of AA were seal in vials under nitrogen and stored at -80°C. Phorbol 12-myristate 13-
acetate (PMA, Calbiochem) was prepared as a stock solution in dimethyl sulfoxide 
(DMSO) and diluted 1,000 times with bath solution. Pertussis toxin [PTX; List Biological 
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Laboratories Inc (Campbell, CA)] was prepared as a stock solution in double-distilled 
water and then diluted 1,000 times in incubation medium five hours before patching cells.  
All chemicals obtained from Sigma-Aldrich Inc. (St. Louis, MO) except where noted. 
 
E. Data Analysis  
The Patch 6.4 and Signal 2.15 software packages (Cambridge Electronic Design, 
Cambridge, U.K.) were used to measure peak inward current of whole-cell traces. The 
trough seeking function of Patch 6.4 was used to determine peak current where indicated.   
Data were further analyzed using EXCEL (Microsoft, Seattle, WA), and ORIGIN 
(Microcal Software, Northampton, MA). Percent inhibition was calculated as  
= ((I-I’)/I)*100  
where I is the control current determined by an average of five whole-cell current 
measurements prior to application of a particular agent and I’ is the average of five 
current measurements at the time specified for the determination. Percent facilitation was 
calculated as  
= ((If-Iu)/Iu)*100  
where If is the facilitated current recorded after a +80 mV depolarization (see description 
above) and Iu is the unfacilitated current. Time to peak was determined using the trough 
seeking function of Patch 6.4 across each sweep of a recording. Conductance was 
calculated from a modified Ohm’s Law equation:  
G = I/(Vm − Vrev)  
where I is the peak current at each test potential, Vm is the test potential, and Vrev is the 
apparent reversal potential.  Relative conductance (G/Gmax )-voltage (Vm) curves were 
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plotted for whole-cell recordings before and after AA application. Data were curve fit 
using the Boltzmann Equation function in the Origin 7.0 software package yielding a 
curve fitting the equation:   
G/Gmax = Gmax + (Gmin-Gmax)/(1 + exp((Vm-Vm½ )/k)) 
 where Gmax is the maximal conductance,  Gmin is the minimal conductance, Vm is the test 
potential, Vm½ is the voltage at half maximal conductance and k is the slope factor. 
 
F. Statistical analyses  
All data are summaries presented as mean ± s.e.m. (standard error of the mean) 
for the designated number of experiments. For multiple comparisons statistical 
significance was determined (Origin 7.0) by a one-way analysis of variance (ANOVA) 
followed by a Tukey multiple-comparison post-hoc test. For comparisons of two groups, 
data were analyzed by unpaired two-sided Student’s t-test for two means; respective p 
values are reported for each comparison. Statistical significance was set at p < 0.05.   
 
G. In situ Hybridization 
Fresh frozen SCG sections were fixed by perfusion with 4% paraformaldehyde in 
0.1 M phosphate buffer, pH 7.4, postfixed for 2 hours in the same fixative and 
cryoprotected overnight in 20% sucrose in 0.1 M phosphate buffer, pH 7.4 before 
blocking and cutting using a cryostat in 8 micron sections for in situ hybridization using 
radioactively end labeled oligonucleotides as described in Bridges, et al. (2003). 
Antisense oligonucleotide sequences were synthesized (Sigma Genosys) to be 
complimentary to nucleotides 599-632 and 760-793 of the rat DAGL alpha sequence 
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(GenBank accession number XM_219575). Oligonucleotides were end-labelled using 
terminal transferase (Promega) and 33P-dATP (Perkin Elmer).  Antisense probes were 
used together in hybridisation in order to increase signal intensity. A competition control 
for the specificity of the signal consisted of addition of a 250 fold excess of unlabelled 
oligonucleotides to the reaction mixture during hybridization. Following appropriate high 
stringency washes and air drying, slides were dipped in autoradiographic emulsion 
(Amersham).  After 5 weeks they were developed, sections counterstained with toluidine 
blue and coverslipped with DPX mountant. Silver grains were visualised with polarized 
epifluorescence microscopy and toluidine blue with brightfield microscopy. 
 
H. Immunohistochemistry 
Rabbit antibodies raised and affinity purified against the GASPTKQDDLVISAR 
epitope in diacylglycerol lipase α (DAGLα) as previously described (Bisogno et al 2003) 
were a generous gift of Prof. Pat Doherty of Kings College.  SCG from adult rats were 
prepared by perfusion fixation with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 
7.4, postfixed for 2 hours in the same fixative and cryoprotected overnight in 20% 
sucrose in 0.1 M phosphate buffer, pH 7.4 before blocking and freezing. Eight micron 
sections were cut using a cryostat. Immunohistochemistry was performed using indirect 
tyramide signal amplification (Perkin Elmer) visualized with Avidin FITC as previously 
described (Michael et al 1999). 
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CHAPTER III 
 
 
 
The Ca2+ Channel β-Subunit 
Determines Whether Stimulation of 
M1 Muscarinic Receptor Enhances or 
Inhibits N-Current 
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Abstract 
 
 
 
In dissociated neurons, stimulation of M1 muscarinic receptors (M1Rs) produces a distinct 
pattern of modulation on N-type calcium (N-) channels, enhancing currents at negative 
test potentials and inhibiting currents elicited with positive test potentials. Exogenously 
applied arachidonic acid (AA) reproduces the same profile of modulation; suggesting AA 
functions as a downstream effector of M1Rs.  In addition, techniques which limit AA 
concentration minimize N-current modulation by M1R stimulation. Still, a role for AA in 
a pathway of modulation remains controversial. Here we used an expression system to 
examine the physiological mechanisms regulating modulation. In the course of the 
investigation we found the N-channel’s β-subunit (CaVβ) acts as a molecular switch 
regulating whether modulation results in enhancement or inhibition. In HEK-293 cells, 
M1R stimulation inhibited activity of N-channels containing CaVβ1b, CaVβ3, or CaVβ4, 
but enhanced activity of N-channels containing CaVβ2a. Exogenously applied AA 
produced the same pattern of modulation.  Our data fit a model in which CaVβ2a blocks 
inhibition, thus unmasking enhancement. Studies with mutated and chimeric CaVβ 
subunits revealed palmitoylation of CaVβ2a as essential for loss of inhibition. These 
results predict that within neurons, modulation of N-channel activity by M1Rs will 
fluctuate between enhancement and inhibition based on the presence of palmitoylated 
CaVβ2a.  
 
 
 
 
 
47 
 
Introduction 
 
All neural function results from a series of electrical and chemical signals. The 
two realms of signaling are often bridged within neurons by voltage-gated calcium 
channels, such as the N-type calcium (N-) channel (Hille 2001).  Changes in voltage 
across cell membranes open N-channels allowing an influx of calcium (N-current).  At 
postsynaptic sites, N-current triggers biochemical changes including: modulation of 
certain ion channels (Wisgirda and Dryer, 1992), enzyme activation (Rittenhouse & 
Zigmond 1999) and gene transcription (Brosenitsch & Katz 2001; West et al., 2002).  
Neurotransmitters bind to G-protein coupled receptors (GPCRs) stimulating signal 
transduction cascades that modulate the N-channel’s response to changing membrane 
potential (Elmslie 2003; Hille 1994).  Some of these pathways are well described, so that 
now; both the molecules in the signaling cascades and the sites of modulation on N-
channels are known (Suh and Hille 2005). Still, other modulating pathways remain 
unresolved. 
The M1 muscarinic receptor (M1R) is one of several Gq-coupled receptors 
(GqPCRs) that modulates N-channels by an incompletely described pathway referred to 
as the slow pathway (Mathie et al. 1992; Suh and Hille 2005).  Recent reports propose a 
reduction in levels of phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] during 
GqPCR stimulation suffices to elicit inhibition (Wu et al., 2002; Gamper et al., 2004; 
Delmas et al., 2005).  In this model channels need to have PtdIns(4,5)P2 bound to 
function. During M1R stimulation PtdIns(4,5)P2  is depleted from the membrane creating 
a concentration gradient which results in PtdIns(4,5)P2  dissociating and diffusing away 
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from the channel.  A similar model of PtdIns(4,5)P2  depletion and dissociation has been 
established as the mechanism that modulates M-current, a voltage-gated potassium 
current sensitive to M1R stimulation.  
However, previously our lab determined modulation of N-current by M1Rs 
requires events downstream of PtdIns(4,5)P2 hydrolysis (Liu et al 2004).  In superior 
cervical ganglion (SCG) neurons, the muscarinic agonist oxotremorine-M (oxo-M) and 
arachidonic acid (AA) elicit the same distinct pattern of modulation (Liu et al. 2001; Liu 
et al. 2003); inhibiting N-current at positive test potentials and enhancing N-current at 
negative test potentials.  M1R stimulation releases AA (Tence et al 1994; Strosznajder & 
Samochocki 1992) suggesting a role in the slow pathway.  Consistent with hypothesis, 
modulation of N-current is minimized when AA levels are reduced by molecular 
techniques (Liu & Rittenhouse 2003; Liu et al. 2004) or pharmacological block (Liu & 
Rittenhouse 2003; Liu et al. 2004; cf Gamper et al 2004).  At present no binding site for 
PtdIns(4,5)P2 or AA on voltage-gated calcium channels has been determined, but we 
have shown the enhancement and inhibition of N-current by AA are discrete molecular 
events with different sites of action (Barrett et al 2001; Liu et al 2001).   
Whether both AA-sensitive sites reside in the same channels or whether two 
distinct channel populations are required to observe enhancement and inhibition remains 
untested.  The expression of channels in a recombinant system allows the examination of 
a homogeneous population of channels.  Therefore, we attempted to recapitulate 
enhancement and inhibition of N-current in HEK-293 cells expressing M1Rs and N-
channels.  N-channels are multimeric complexes defined by a large pore-forming subunit 
(CaV2.2), which is modified by ancillary subunits α2δ and CaVβ (Catterall 2000). We 
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intended to use the power of mutagenesis to study enhancement and inhibition 
independently.  In doing so, we made the serendipitous discovery that enhancement and 
inhibition separate without mutagenesis, but simply by varying the composition of wild 
type CaVβ.  In particular, the N-currents obtained from channels comprising the CaVβ2a 
subunit were uniquely enhanced by either M1R stimulation or application of AA. 
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Results  
 
M1R elicited inhibition of N-current is blocked by OPC 
In SCG neurons M1R stimulation inhibits N-current via the release of (an) 
unknown diffusible second messenger(s). Previously we found this inhibition is 
minimized by the PLA2 antagonist oleyloxyethyl phosphocholine (OPC; Liu & 
Rittenhouse 2003; Liu et al 2004). We first tested whether in recombinant cells, N-
currents were inhibited by M1R stimulation and if the inhibition was sensitive to OPC.  
An HEK-293 cell line stably transfected with M1Rs (HEK-M1; Peralta et al 1988) was 
transiently transfected with these N-channel subunits: CaV2.2e the N-channel variant 
found in SCG neurons (Lin et al 1997); CaVβ3, which most commonly associates with 
CaV2.2 (Witcher et al. 1993; Dolphin 2003); and α2δ-1 which is expressed in SCG 
(Comm D Lipscombe). In whole cell recordings, a sixty-second exposure to the 
muscarinic agonist oxotremorine-M (oxo-M; 10 µM) inhibited N-current by 61± 9 % (n = 
16; Figs. 3-1 a,b,g). In a parallel experiment tsA cells stably transfected with CaV2.2e, 
α2δ-1 and CaVβ3 and transiently transfected with the M1R, oxo-M inhibited current by 70 
± 17 % (n = 5; Figs. 3-1 c,d,g), ruling out a system-specific effect. In contrast, OPC 
reduced current inhibition by oxo-M to 2 ± 6 % (n = 7; Figs. 3-1 e,f,g), indicating that in 
the recombinant system, as with SCG neurons, (Liu & Rittenhouse 2003a; Liu et al 
2004), PLA2 participates in N-current inhibition by M1Rs (Fig. 3-1 h). 
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CaVβ subunit controls responses of modulation by M1Rs 
We next sought to examine the dependence of N-current enhancement on M1R 
stimulation and AA release.  Since modulation of N-current in dissociated SCG neurons 
is voltage-sensitive (Liu et al., 2003a), we compared current-voltage (I-V) plots measured 
before and after 90 seconds of oxo-M exposure.  Based on previous work with 
dissociated neurons we expected to observe currents enhanced at negative test potentials.  
However, oxo-M inhibited current at virtually all voltages (Fig. 3-2 i). 
In addition to incomplete recapitulation of M1R modulation, the recombinant N-
current exhibited robust, fast inactivation (Figs. 3-1 b,d and 3-2 h) as previously 
observed with N-current (Olcese et al 1994). In contrast, native N-currents in SCG 
neurons exhibit kinetics with little inactivation (Plummer et al., 1989) which may be 
indicative of CaVβ2a expression (Cahill et al 2000).  Since CaVβ2a transcripts are present 
in SCG neurons (Lin et al 1997), we hypothesized CaVβ2a-containing channels could 
form the major portion of N-current in SCG neurons. If so, CaVβ2a-containing channels 
might exhibit both inhibition and enhancement.  Application of oxo-M to cells expressing 
CaVβ2a rapidly inhibited peak inward current within one minute. However, unlike CaVβ3, 
after three minutes the initial inhibition gave way to a steady state enhancement of +21.5 
± 3.8% in 5 of 5 recordings, (Figs. 3-2 d,e and Fig. 3-4 a).  To determine whether 
enhancement is voltage-sensitive, we compared I-V plots measured before and after 
application of oxo-M.  With CaVβ2a expression, oxo-M no longer inhibited current at any 
potential, but enhanced current approximately 2-fold at negative test potentials (Fig. 3-2 
f).   
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Although we hypothesized expression of CaVβ2a would elicit enhancement at 
negative potentials, the complete loss of inhibition at all potentials was unanticipated.  
Likewise, we did not anticipate CaVβ3 to yield inhibition exclusively. We next asked if 
CaVβ subunits other than CaVβ2a exhibit both inhibition and enhancement.  Four genes 
encode the CaVβ isoforms (Birnbaumer et al.1998).  Therefore, the above experiments 
were repeated with two other neuronal CaVβs; CaVβ1b and CaVβ4.  In each case the 
application of oxo-M rapidly inhibited peak inward current.  We found with the exception 
of CaVβ2a expressing cells, the initial inhibition receded only slightly within 90 seconds, 
reaching a stable inhibition which persisted until washout of oxo-M.  When CaVβ1b was 
expressed, currents were stably reduced in 5 of 7 recordings of -41.8 ± 14.4% (Fig. 3-2 
a,b and Fig. 3-4a).  When CaVβ4 was expressed, currents were stably reduced in 6 of 6 
recordings of -56.2 ± 10.8 % (Fig 3-2 j,k and Fig 3-4a).  These data are similar to those 
obtained from cells expressing CaVβ3 in which a three minute exposure to oxo-M elicited 
inhibition in 8 of 9 recordings with an average change of -54 ± 10% (Figs. 3-2 g,h and 
Fig. 3-4a). Also, as with CaVβ3, when either CaVβ1b or CaVβ4 was expressed, oxo-M 
inhibited current at all voltages (Fig. 3-2 c,l).  No significant difference in current 
modulation occurred among CaVβ1b, CaVβ3, or CaVβ4 (p > 0.05, ANOVA).  Percent 
change in current amplitude was highly significant between CaVβ2a and CaVβ1b, CaVβ3, 
or CaVβ4, (p < 0.005 ANOVA; Fig. 3-4a).  These data indicate that channels containing 
CaVβ2a exhibit unique N-current modulation by M1Rs. 
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AA elicits a similar profile of N-current modulation as elicited by the M1R 
In previous studies we found exogenous AA mimics N-current modulation by 
M1Rs (Liu et al., 2003). We hypothesized AA also would inhibit or enhance recombinant 
N-current according to the same restrictions as M1R stimulation. Therefore, we examined 
modulation by AA on whole-cell currents from HEK-M1 cells transfected with N-
channel subunits comprising one of the four different CaVβ subunits specified earlier.  
AA (10 µM) initially enhanced currents (Fig. 3-3 a,d,g,j).  However, enhancement was 
transient and after a three minute exposure to AA subsequent inhibition dominated the 
currents of channels containing CaVβ1b (by -58.5 ± 14.4% in 3 of 3 recordings; Fig. 3-3 
a,b and 3-4 b), CaVβ3 (by -44.2 ± 9.1% in 5 of 5 recordings; Fig. 3-3 g,h and 3-4 b), or 
CaVβ4 (by -26.0 ± 6.7% in 5 of 5 recordings; Fig. 3-3 j,k and 3-4 b).  Conversely, when 
CaVβ2a was expressed, the initial enhancement remained stable at +54 ± 12% in 5 of 5 
recordings (Fig. 3-3 d,e and 3-4 b).  Percent change in current was highly significant 
between CaVβ2a and CaVβ1b, CaVβ3, or CaVβ4, (p ≤ 0.005 ANOVA).  No statistical 
difference occurred among CaVβ1b, CaVβ3, or CaVβ4 (p > 0.05, ANOVA) (Fig. 3-4 b). 
Enhancement of N-current by AA, like oxo-M, is voltage-sensitive in dissociated 
SCG neurons (Barrett et al 2001; Liu et al., 2001; Liu et al., 2003) therefore we tested the 
effect of AA on I-V relationships before and after AA application.  When CaVβ2a was 
expressed, AA enhanced current at negative potentials, and did not inhibit current at any 
potential (Fig. 3-3 f). In contrast, AA strongly inhibited current at positive voltages when 
CaVβ1b, CaVβ3, or CaVβ4 (Fig. 3-3 c,i,l) was expressed.  There was a slight enhancement 
of current at negative potentials (Fig 3-3 i,l), but it was not statistically significant. 
Overall, the pattern of modulation elicited by AA, separation of enhancement and 
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inhibition based on CaVβ expression, matches the pattern of modulation observed with 
M1R stimulation (See Fig 3-4; Compare Figs. 3-2 and 3-3).   
AA reproduced the modulation elicited by M1Rs, corroborating the previous 
assertion that AA is a component of the slow pathway (Liu & Rittenhouse, 2003; Liu et 
al., 2004).  Still, if enhancement and inhibition are attributable to the presence of AA, 
they should reverse following washout of AA.  We found previously in SCG neurons 
(Liu et al., 2001) that AA’s hydrophobic properties made wash out difficult unless the 
bath solution contained fatty-acid free bovine serum albumin (BSA). As with SCG 
neurons, washing cells with copious amounts of bath solution slowly reversed inhibition 
of N-current from CaVβ3-containing channels, but did not reverse enhancement of N-
current from CaVβ2a-containing channels (Fig. 3-3 d,g).  Enhancement of N-current in 
cells expressing CaVβ2a by AA readily reversed when washed with 1 mg/ml BSA  (Fig. 
3-5 a-d) as did inhibition of N-current from CaVβ1b and CaVβ4-containing channels. 
(Figs. 3-3 a,j).  If enhancement is directly attributable to AA it should recur with a 
second application of AA following wash with BSA.  Accordingly we found 
enhancement reversed rapidly when cells were washed with BSA, and upon reapplication 
of AA, enhancement recurred within the same cell (Fig. 3-5 a,c,d).  These data indicate 
both enhancement and inhibition are reversible effects which can be elicited by AA.  
 
A model for dual modulation effects of N-current  
Previous work established enhancement and inhibition as distinct molecular 
events with distinct sites of action (Liu et al., 2001; Barrett et al., 2001). The separation 
of enhancement and inhibition by CaVβs presented a molecular tool to probe the two 
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sites. We postulated every CaV2.2e has a site of enhancement based on the observation 
that all recombinant currents exhibit an initial enhancement with AA (Fig. 3-3 a,d,g,j). 
Since enhancement of N-current in SCG neurons presents as a leftward shift in voltage 
sensitivity (Barrett et al., 2001), we constructed normalized conductance-voltage plots to 
determine whether a leftward shift in voltage sensitivity occurs with N-channels 
containing CaVβs other than CaVβ2a. As shown, both CaVβ2a- and CaVβ3-containing 
cells exhibited a negative shift in conductance in response to AA (Fig. 3-6 a,b). This 
treatment of the data indicates AA increases channel voltage sensitivity independently of 
CaVβ subunit expression.  These data indicate the unique effects of CaVβ2a stem from an 
attenuation of inhibition, rather than a change of enhancement (Fig 3-6 c).  
 
Expression of multiple CaVβ isoforms produces heterogeneous currents 
The above observations yield a possible explanation for why we previously 
observed both enhancement and inhibition of whole-cell N-current in SCG neurons 
(Barrett et al., 2001; Liu & Rittenhouse, 2003; Liu et al., 2004).  Diversity in N-channel 
function has been attributed to a heterogeneous expression of CaVβ in neurons (Scott et al 
1996). In recombinant systems the expression of multiple CaVβ subunits results in a 
mixed population of channels (Jones et al 1998).  Therefore individual SCG neurons may 
exhibit enhancement and inhibition because CaV2.2e co-assembles with different CaVβs. 
To recapitulate the pattern of modulation from SCG, HEK-M1 cells were transfected 
with both CaVβ2a and CaVβ. We found when CaVβ2a was in ten fold excess of CaVβ3, 
the I-V plots recapitulated wild-type I-V plots with enhancement occurring at negative 
voltages and inhibition at positive voltages (Fig. 3-7 a-c). However unlike wild-type 
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current, the currents rapidly inactivated (Fig. 3-7 a,b). SCG neurons express CaVβ2a, 
CaVβ3 and CaVβ4 mRNA with trace amounts of CaVβ1b (Lin et al., 1996).  Therefore, we 
transfected cells with equal amounts CaVβ3 and CaVβ4 and a ten-fold excess of  CaVβ2a, 
and found these cells closely recapitulated both the I-V relationship and the current 
kinetics of SCG neurons under control conditions and following M1R stimulation by oxo-
M (Fig. 3-7 d-f).  These data corroborate previous work indicating within neurons a 
heterogeneous population of N-channels exhibit unique functional properties based on the 
expression of CaVβ subtype.  Moreover, within a neuron, at specific locations, calcium 
influx may be enhanced or inhibited during modulation depending on CaVβ expression. 
 
Loss of Palmitoylation Restores Partial Inhibition of Channels by Oxo-M or AA 
We next asked what structural feature of CaVβ2a accounts for the attenuation of 
inhibition.  A unique conspicuous feature of CaVβ2a is its palmitoylation near the N-
terminus (Chien et al. 1996).  Since CaVβ2a interferes with a fatty acid mediated 
inhibition, it raised the possibility of direct antagonism by palmitic acid at a site of 
modulation by AA.  We therefore tested the importance of palmitoylation by 
coexpressing in HEK-M1 cells CaV2.2e, α2δ-1 and a CaVβ2a mutated at the two sites of 
palmitoylation [CaVβ2a(C3,4S); Chien et al 1996].  In these cells oxo-M caused an initial 
transient inhibition, which subsided leaving the current close to control levels a change in 
current magnitude of -1.53 ± 7.3% (p = 0.07 vs. wild type CaVβ2a).  (Fig. 3-8 a,c and 
Fig. 3-10).  Oxo-M enhanced current in 6 of 12 recordings and inhibited current in the 
remaining recordings.  In these same cells AA (10 µM) initially enhanced current 
amplitude; however unlike with wild type CaVβ2a, subsequent inhibition followed (Fig. 
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3-8 b,d and Fig. 3-10).  Now rather than enhance current, AA reversibly inhibited current 
by -16.5 ± 6.9% in 7 of 9 recordings, a significant change from CaVβ2a (p = 0.0002).  
Still, the magnitude of inhibition was less than observed with wild types CaVβ subunits 
other than CaVβ2a. These data suggest palmitoylation of CaVβ2a is necessary to switch 
modulation from inhibition to enhancement.  However, the loss of palmitoylation by 
itself does not confer complete restoration of full inhibition obtained with non-
palmitoylated wild type CaVβ subunits. 
To further test whether palmitoylation is both necessary and sufficient to block 
current inhibition by oxo-M or AA, we tested a chimeric CaVβ in which the initial sixteen 
amino acids from the N-terminus of CaVβ2a replaced fifteen amino acids in the 
corresponding region of CaVβ3 (CaVβ2aβ3).  This N-terminus substitution adjoins 
palmitoylation to normally non-palmitoylated CaVβ isoforms (Chien et al 1998).  In 
HEK-M1 cells expressing CaV2.2e, α2δ-1 and CaVβ2aβ3, oxo-M inhibited peak current 
in 5 of 6 recordings, -14.5 ± 5.9 % and recovered upon wash out of agonist (Fig. 3-9 a,b 
and Fig 3-10) When AA was applied, current was inhibited by -51.9 ± 8.5 % in 7 of 7 
recordings, which reversed when cells were washed with 1 mg/ml BSA (Fig. 3-9 d,e and 
Fig. 3-10).  I-V plots taken before and 90 seconds after application of oxo-M or AA 
showed inhibition at positive test potentials (Fig. 3-9 c,f).  These data indicate the 
addition of palmitoyl side chains did not reproduce the stable enhancement by oxo-M or 
AA normally observed with wild type CaVβ2a.  
The data suggest other structural domains of CaVβ2a subunit may contribute to 
the block of inhibition in addition to palmitoylation. CaVβ subunits have two highly 
conserved regions separating three highly variable regions (for review see Dolphin 2003).  
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Replacing the N-terminus in the CaVβ2aβ3 chimera substituted the first variable region of 
CaVβ3 leaving the two others intact; a variable region at the center of the peptide and the 
variable carboxy terminus. To ascertain the effect of other CaVβ variable regions on 
modulation, we tested a second chimera in which the N-terminus sixteen amino acid 
residues of CaVβ2a replaced fifty-seven amino acids of the N-terminus of CaVβ1b.  Since 
CaVβ1b shares highest sequence homology to CaVβ2a (Birnbaumer et al. 1998), we 
hypothesized that expression of a CaVβ2aβ1b chimera would allow less inhibition of N-
current than the CaVβ2aβ3 chimera if the protein contributed to the block of inhibition.  
As expected, oxo-M or AA inhibited currents less with CaVβ2aβ1b than CaVβ2aβ3.  AA 
still inhibited currents in 7 of 9 recordings, -6.9 ± 8.0 % (Fig. 3-9 j,k and Fig. 3-10); 
however inhibition was significantly less than with the CaVβ2aβ3 chimera (p ≤ 0.02).  
Oxo-M now no longer inhibited, but enhanced current by +18.8 ± 10.2 % in 4 of 4 
recordings (Fig. 3-9 g,h and Fig. 3-10).  This reversal of modulation by oxo-M was 
significantly different from that observed with the CaVβ2aβ3 chimera (p ≤ 0.04). 
Comparisons of I-Vs, measured prior to and 90 seconds after oxo-M or AA both showed 
enhancement of current at negative test potentials (Fig. 3-9 i,l) for cells expressing the 
CaVβ2aβ1b chimera.  Thus CaVβ subunits with identical palmitoylated N-termini (wild 
type CaVβ2a and the two aforementioned chimerae) have significantly different effects on 
the channel’s response to modulation by oxo-M or AA.  These data indicate that 
structural features of CaVβ2a in addition to the palmitoylated N-terminus contribute to 
blocking inhibition and consequently revealing enhancement. 
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Discussion 
 
Here we used a recombinant system to investigate the enhancement and inhibition 
of N-current that occurs during M1R stimulation and AA application. In so doing we 
made the serendipitous discovery that the N-channel’s β subunit directs opposite effects 
of N-current modulation. Specifically, M1R stimulation or exogenous AA uniquely 
enhanced N-currents from whole-cell recordings of cells expressing CaVβ2a.  This 
finding allowed us to further examine the modulation of N-current and reach several 
conclusions. First, the striking recapitulation of M1R induced modulation by AA, coupled 
with the loss of modulation when AA is blocked or sequestered is strong evidence that 
AA is an integral component of the slow pathway.  Second, the unique effect of CaVβ2a 
provided a molecular tool to probe the mechanism by which currents may be enhanced or 
inhibited. Third, cells expressing multiple forms of CaVβ subunits displayed both 
inhibition and enhancement of currents during modulation, implying the characteristic 
pattern of modulation observed in SCG neurons results from a heterogeneous distribution 
of CaVβ isoforms.  Fourth, using mutated and chimeric CaVβ constructs we demonstrated 
palmitoylation of CaVβ2a is a key feature in its capacity to toggle modulation from 
inhibition to potentiation.  
  
AA is necessary for slow pathway inhibition 
Previously, to demonstrate a role for AA in inhibition, we used pharmacological 
agents, the AA scavenger BSA, antibodies dialyzed internally, and neurons harvested 
from PLA2-/- knockout mice (Liu et al 2004; Liu and Rittenhouse 2003; Liu et al., 2006). 
The block of inhibition by CaVβ2a provides a highly specific agent to dissect the slow 
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pathway, while non-palmitoylated wild type CaVβ subunits conveniently act as negative 
controls. Thus, expression of CaVβ2a can be used as one might use a specific peptide or 
antibody. The data we have presented here support our previous findings in SCG neurons 
in which we found AA is necessary for slow pathway inhibition elicited by M1Rs. 
It must be stressed none of the findings reported here minimize the role of 
PtdIns(4,5)P2 in N-current modulation, but rather document a requirement for AA in 
modulation.  It is well documented that PtdIns(4,5)P2 breakdown is necessary for slow 
pathway inhibition (Suh and Hille 2005; Wu et al 2002; Gamper et al 2004; Delmas et al 
2005; Liu et al 2004; Liu and Rittenhouse 2003); whether or not events downstream of 
PtdIns(4,5)P2 breakdown are necessary remains controversial (Gamper et al 2004; 
Delmas et al 2005).  Recent reports on calcium channel inhibition have led to the 
conclusion that depletion of PtdIns(4,5)P2 is both necessary and sufficient to elicit 
inhibition of voltage gated channels CaV2.2 and CaV2.3 (Gamper et al 2004; Wu et al 
2002, reviewed in Suh and Hille 2005).  Our data indicate AA production is both 
necessary and sufficient to elicit inhibition of CaV2.2 (Liu et al 2004; Liu and 
Rittenhouse 2003, Liu et al 2006).  
A resolution to the paradox would entail a role for both PtdIns(4,5)P2 acting on 
the channel and AA either directly or indirectly.  A model for PtdIns(4,5)P2 and AA 
opposing each other in modulation of potassium channels has been published (Oliver et 
al., 2004), in which PtdIns(4,5)P2 and AA act at different sites of the channel.  A direct 
interference is possible since AA is an integral piece of the PtdIns(4,5)P2 molecule and 
thus could compete for binding. Indirect actions of PtdIns(4,5)P2 and AA must be 
considered as both are bioactive molecules with multiple downstream effects. 
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A Working Model for the Enhancement and Inhibition 
Previously we characterized enhancement and inhibition result as distinct 
molecular events acting at different sites of the channel through experiments with 
exogenous AA on isolated N-current in SCG neurons (Barrett et al 2001). Restriction of 
AA movement across the cell membrane indicated enhancement requires AA on the 
extracellular side, while inhibition requires AA on the intracellular side (Barrett et al 
2001).  Since CaVβ subunits are cytoplasmic, we hypothesized that CaVβ2a attenuates 
inhibition without affecting enhancement.  In dissociated neurons, AA induces an initial 
current enhancement followed by a slower progressing inhibition (Liu et al 2001; Barrett 
et al 2001).  The simplest explanation for these data is that the initial enhancement 
becomes masked by the subsequent more dominant inhibition. Since previous work 
indicated enhancement stems from increased voltage sensitivity (Barrett et al 2001) we 
used normalized G-V curves to show an increase in voltage sensitivity occurs 
independently of CaVβ2a expression.  In contrast, inhibition results from an increase in 
steady state inactivation (Liu & Rittenhouse 2000). This type of inhibition would 
essentially reduce the available number of channels providing calcium influx, dominating 
an enhancement produced by a shift in voltage sensitivity.  Thus by blocking a dominant 
inhibition CaVβ2a unmasks a latent enhancement. 
The masking of enhancement offers some explanation for the observation that the 
majority of studies on N-current modulation have focused on inhibition (Elmslie 2003). 
Still, the generation of enhancement and inhibition has been reported from experimental 
systems similar to the one we used here. For example, AA causes both a shift in 
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activation towards negative potentials and a simultaneous increase steady state 
inactivation in T-channels (Talavera et al 2004).  Also, in SCG neurons, the amide of 
AA, anandamide, elicited enhancement at negative potentials and inhibition at positive 
potentials in I-V plots (Guo and Ikeda, 2003).  A recent report showed muscarinic 
enhancement reported R-type channels in hippocampal neurons involved a leftward shift 
in voltage sensitivity (Tai et al., 2006). It should be noted the hippocampus is one brain 
region where CaVβ2a is highly expressed (Day et al 1998). Finally, in an earlier report 
using HEK-293 cells, transiently transfected with recombinant M1Rs and N-channels 
containing CaVβ3 showed carbachol inhibited calcium current without enhancing.  
However, the I-V curves presented showed a discernible leftward shift in voltage 
sensitivity (Melleti et al 2001).  
 
A role for the CaVβ2a N-terminus 
We determined the palmitoylation at the N-terminus of CaVβ2a is necessary to 
invert modulation.  However, palmitoylation by itself cannot account for the complete 
reversal of modulation.  Inhibition that was recouped by removal of palmitoylation was 
substantially less than inhibition observed with wild type non-palmitoylated CaVβ 
isoforms.  Also, addition of the palmitoylated CaVβ2a N-terminus to the CaVβ2aβ3 
chimera did not recover enhancement elicited by AA or oxo-M. These data indicate 
aspects of the CaVβ2a N-terminus other than palmitoylation influence modulation.  
Several possible models can explain how the CaVβ2a acts as a whole to affect 
modulation.   
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One possibility is that the palmitoyl side chains of the CaVβ2a subunit directly 
interfere with the actions of AA.  In this model the CaVβ2a attaches to CaV2.2e, such that 
the palmitoyl side chains are positioned to produce steric hindrance to AA binding.  In 
the CaVβ2aβ3 chimera the palmitoyl chains are positioned differently due to the altered 
structure of the subunit.  This would explain why AA inhibition is not blocked by the 
CaVβ2aβ3 chimera. However, exclusion of palmitoyl chains on the CaVβ2a(C3,4S) 
mutant does not allow inhibition as seen in wild-type non-palmitoylated CaVβ subunits, 
so other aspects of the N-terminus m contribute to the block of inhibition. 
Another possibility is that the N-terminus blocks inhibition by tethering 
PtdIns(4,5)P2 to CaV2.2e. The two palmitoylated cysteines of the N-terminus of CaVβ2a 
are in close proximity to a concentration of basic residues.  The amino acid sequence of 
the N-terminus is: MQCCGLVHRRRVRVSY (sites of palmitoylation in bold italics, 
cationic residues underlined and in bold).  Such a concentration of cationic residues is 
known to bind PtdIns(4,5)P2  (Oliver et al., 2004; Robbins et al., 2006).  In fact a series of 
different palmitoylated peptide oligomers rich in cationic residues all reduce M-current 
and block further inhibition by M1R agonists, presumably by sequestering PtdIns(4,5)P2  
(Robbins et al., 2006).  The CaVβ2a N-terminus may act as a PtdIns(4,5)P2  docking site, 
tethering a molecule to the channel so that it does not dissociate during depletion of 
PtdIns(4,5)P2, nor is it supplanted by high concentrations of AA, thus making the channel 
immune to inhibition.  In this model, removal of palmitoylation would permit greater 
diffusion of PtdIns(4,5)P2 from the channel allowing for some inhibition, but the cationic 
residues would slow the dissociation of PtdIns(4,5)P2 from the channel, making the 
inhibition substantially less than obtained with wild-type non-palmitoylated CaVβ 
64 
isoforms. If the model described above is correct then the PtdIns(4,5)P2 docking site 
formed by the CaVβ2a N-terminus must be positioned properly in order to function as 
block of inhibition. Accordingly, the PtdIns(4,5)P2 sequestering palmitoylated peptides 
that block M-current inhibition do block N-current modulation elicited by M1R 
stimulation (Robbins et al 2006).  Since the variable regions of CaVβ3 share little 
homology with those of CaVβ2a the PtdIns(4,5)P2 molecule may be tethered, but not at 
the correct site of the channel.  Accordingly, addition of palmitoylation to the CaVβ2aβ1b 
chimera, a construct more homologous with CaVβ2a, allowed significantly less inhibition 
by AA and recovered enhancement by oxo-M.   
 
A role for Multiple CaVβ Isoforms in Neurons 
Here we have shown multiple CaVβ isoforms expressed in a recombinant system 
can recapitulate the enhancement and inhibition of N-current modulation observed in 
neurons.  Given the diversity of neuronal functions for calcium influx, there must be 
localized control of a channel’s response to modulation.  Our findings provide a 
previously unrecognized role for CaVβ subunits in modulation and represent a means by 
which either M1R stimulation or AA release can have diverse effects in a single cell. 
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Figure 3-1. M1R Induced Inhibition of Recombinant N-current is Blocked by PLA2 
Antagonist. HEK-M1 cells were transiently transfected with N-channel subunits CaV2.2e, 
α2-δ-1 and CaVβ3. Modulation of N-current by M1R stimulation is demonstrated by (a) 
time courses of peak inward current using 5 mM Ba as charge carrier; before, during and 
after a 3 min bath application of oxo-M (10 µM), (b) representative whole-cell current 
traces taken from the respective time course prior to (▬), 1 min after (▬) oxo-M 
application and, 1 min after wash (▬). Cells were held at -90 mV for the recordings in 
this and all subsequent figures. Currents were elicited every 4 sec by stepping to a test 
potential of 0 mV for 100 ms unless noted. Vertical portion of black bars in 
representative sweeps correspond to 0.4 nA, horizontal portion corresponds to 20 msec.  
(c, d) Modulation of N-current from tsA cells with stably transfected N-channel subunits 
CaV2.2e, α2-δ-1 and CaVβ3; transiently expressing M1R is shown in time course and 
representative sweeps as described above. The charge carrier was increased to 20 mM Ba 
to improve signal to noise ratio, and accordingly the test potential was adjusted to 10 mV 
for surface-potential shift.  (e,f) N-current modulation from cells expressing HEK-M1 
cells transfected as for a and b.  Here cells were exposed to PLA2 antagonist OPC for at 
least 3 minutes prior to  application of Oxo-M (g) Summary of inhibition after 1 min of 
exposure to Oxo-M. (h) Data supports working model of slow pathway depicted in 
schematic in which PLA2 is necessary component to elicit N-current inhibition.  
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Figure 3-2. CaVβ Subunit Expression Determines N-current Response to Modulation by 
M1R Stimulation. HEK-M1 cells were transiently transfected with CaV2.2e, α2-δ-1 and 
various CaVβ subunits. Modulation of N-current in cells expressing CaVβ1b by M1R 
stimulation is demonstrated by (a) time courses of peak inward current using 5 mM Ba as 
charge carrier; before, during and after a 3 min bath application of oxo-M (10 µM), (b) 
representative whole-cell current traces taken from the respective time course prior to 
(▬) and 3 min after (▬) oxo-M application and, (c) averaged normalized I-V plots 
before (●) and after (o) oxo-M application (n = 6). Currents were elicited every 4 sec by 
stepping to a test potential of 0 mV for 100 ms unless noted. (d-e) Modulation of N-
current from cells expressing CaVβ2a. The charge carrier was increased to 20 mM Ba to 
improve signal to noise ratio, and the test potential was adjusted to 10 mV for surface-
potential shift.  (f) Averaged normalized I-V plots for cells expressing CaVβ2a (n = 5). (g-
h) Time course and representative sweeps of N-current modulation from cells expressing 
CaVβ3 using 20 Ba for charge carrier with test potential of 10 mV (compare to Fig 2-1 
a,b). (i) Averaged normalized I-V plots for cells expressing CaVβ3 measured in 5 Ba (n = 
3) (j-l) Demonstration of N-current modulation from cells expressing CaVβ4. Time 
course, representative sweeps, and averaged normalized I-V plots (n = 3) measured in 5 
Ba.  A second set of I-V plots measured in 20 Ba showed the same pattern of modulation, 
inhibition without enhancement (n = 3, data not shown). For current-voltage plots, the 
test potential was stepped in 10 mV increments from -60mV to +70 mV.  Black bars in 
representative sweeps correspond to 0.4 nA.   
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Figure 3-3. CaVβ Subunit Determines N-current response to Modulation by Exogenous 
Arachidonic Acid (AA). HEK-M1 cells were transiently transfected with CaV2.2e, α2-δ-1 
and various CaVβ subunits. Modulation of N-current in cells expressing CaVβ1b by AA 
application is demonstrated by (a) time courses of peak inward current using 5 mM Ba as 
charge carrier; before, during and after a 3 min bath application of oxo-M (10 µM), (b) 
representative whole-cell current traces taken from the respective time course prior to 
(▬) and 3 min after (▬) AA application and, (c) normalized I-V plots before (●) and 
after (o) AA application (n = 4). Currents were elicited every 4 sec by stepping to a test 
potential of 0 mV for 100 msec. Washout of AA was enhanced by the addition of 1 
mg/ml BSA. (d-e) Modulation of N-current by AA from cells expressing CaVβ2a. The 
charge carrier was increased to 20 mM Ba and the test potential was adjusted to 10 mV 
for surface-potential shift. (f) Averaged normalized I-V plots for cells expressing CaVβ2a 
(n = 5). (g-i) N-current modulation from cells expressing CaVβ3 in 5 Ba, averaged 
normalized I-V plots (n = 5).  (j-l) Demonstration of N-current modulation from cells 
expressing CaVβ4 in 5 Ba. averaged normalized I-V plots (n = 5). Again, washout of AA 
was enhanced by the addition of 1 mg/ml BSA.  For current-voltage plots, the test 
potential was stepped in 10 mV increments from -60mV to +70 mV.  Black bars in 
representative sweeps correspond to 0.4 nA.   
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Figure 3-4. Summary of Data from Whole-Cell Recordings from HEK-M1 Cells 
Expressing N-channels Comprising Various Wild-type CaVβ.  Shown are (a) a summary 
of inhibition by oxo-M after 3 minutes, and (b) a summary of inhibition after a three 
minute exposure to AA. ** denotes statistical significance (p ≤ 0.005) as determined by 
one way ANOVA. 
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Figure 3-5. Absorption of AA Minimizes Enhancement of Current. HEK-M1 cells were 
transiently transfected with CaV2.2e, α2-δ-1 and CaVβ2a. Modulation of N-current by AA 
application is demonstrated by (a) time courses of peak inward current using 20 mM Ba 
as charge carrier; before, during and after two separate 3 min bath applications of AA (10 
µM) washout of AA was achieved by bath application of 1 mg/ml BSA, (b) 
representative whole-cell current traces taken from the respective time course prior to 
(▬), 3 min after (▬) AA application and 1 min after washout (▬). Currents were 
elicited every 4 sec by stepping to a test potential of 0 mV for 100 ms to accentuate 
enhancement of current.  As shown BSA reverses potentiation by AA and second 
application of AA repeats enhancement.  (c) Comparison of I-V plots before (●) and after 
(o) AA application shows characteristic enhancement at negative potentials. (d) 
Comparison of I-V plots taken after washout of AA by BSA (●) and after (o) second 
application of AA shows same characteristic enhancement at negative potentials. 
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Figure 3-6 CaVβ2a Blocks Inhibition of N-current Revealing Latent Enhancement.  
Using a modified Ohm’s law G = I/(Vm − Vrev) where I is the peak current at each test 
potential, Vm is the test potential, Vrev is the apparent reversal potential, and Gmax as the 
maximal conductance we plotted G/Gmax vs  Vm for whole-cell recordings before and 
after AA application and found both (a) CaVβ2a and (b) CaVβ3 containing cells exhibited 
a negative shift in conductance as a response to AA modulation.  These findings indicate 
that both channels exhibit enhancement.  (c) Schematic representation of working model.  
Previous work had shown that extracellular events control enhancement and intracellular 
events control inhibition. We reasoned that since CaVβ binds to cytoplasmic regions of 
CaV2.2e the anomalous response of CaVβ2a was due to alterations in inhibition.  We 
therefore propose a model in which CaVβ2a allows enhancement by blocking a normally 
dominant inhibition. 
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Figure 3-7. Multiple CaVβ Subunit Expression Recapitulates Modulation Pattern of SCG 
Neurons. HEK-M1 cells were transiently transfected with N-channel subunits comprising 
multiple CaVβ subunits. Modulation of N-current by application of AA (10 µM) is in 
HEK-M1 cells expressing CaV2.2e, α2-δ-1, CaVβ2a, and CaVβ3 in a 12:12:10:1 ratio 
demonstrated by representative whole-cell current traces using 20 Ba as a charge carrier, 
stepping to a test potential of (a) -10 mV or (b) +10 mV, prior to (▬) and 90 seconds 
after (▬) AA application, and (c) normalized I-V plots before (●) and after (o) AA 
application. Modulation of N-current by application of Oxo-M (10 µM) is in HEK-M1 
cells expressing CaV2.2e, α2-δ-1, CaVβ2a, CaVβ3, and CaVβ4 in a 12:12:10:1:1 ratio 
demonstrated by representative whole-cell current traces using 20 Ba as a charge carrier, 
stepping to a test potential of (d) -10 mV or (e) +10 mV, prior to (▬) and 90 seconds 
after (▬) AA application, and (f) normalized I-V plots before (●) and after (o) Oxo-M 
application. 
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Figure 3-8 Loss of Palmitoylation Restores Inhibition of N-current by M1R Stimulation 
or AA Application.  HEK-M1 cells were transiently transfected with CaV2.2e, α2-δ-1 and 
CaVβ2a(C3,4S), mutated at the two sites of palmitoylation. (a,b) Representative whole-
cell current traces using 20 Ba as a charge carrier, stepping to a test potential of  10 mV 
taken prior to (▬) three minutes after application of oxo-M or AA (▬) and one minute 
after washout of oxo-M or AA (▬) show similar pattern of inhibition and recovery. 
Vertical portion of black bars in representative sweeps correspond to 0.4 nA, horizontal 
portion corresponds to 20 msec.  In time courses (c) oxo-M inhibits current transiently 
continued exposure to oxo-M returns current near level before oxo-M application. (d) AA 
initially enhances but, unlike wild- type CaVβ2a subsequently inhibits current. Washout 
of AA with 1 mg/ml restores current. 
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Figure 3-9. Addition of Palmitoylation to Chimeric CaVβ Attenuates Inhibition. HEK-
M1 cells were transiently transfected with CaV2.2e, α2-δ-1 and either CaVβ2aβ3 chimera 
or CaVβ2aβ1b chimera. Modulation of N-current by Oxo-M (10 µM) from cells 
expressing CaVβ2aβ3 chimera is shown through (a) time courses of peak inward current; 
before, during and after a 3 min bath application of oxo-M, (b) representative whole-cell 
current traces taken from the respective time course prior to (▬), 3 min after (▬) oxo-M 
application and, 1 min after wash (▬). (c) Averaged normalized I-V plots before (●) and 
after (o) oxo-M application (n = 4). (d,e,f) Modulation of N-current by AA (10 µM) from 
cells expressing CaVβ2aβ3 chimera is shown as above by representative time course, 
sweeps, and averaged normalized I-V (n = 7). (g,h,i) Modulation of N-current by Oxo-M 
(10 µM) from cells expressing CaVβ2aβ1b chimera is shown as above by representative 
time course, sweeps, and averaged normalized I-V (n = 4). (j,k,l) Modulation of N-
current by AA (10 µM) from cells expressing CaVβ2aβ1b chimera is shown as above by 
representative time course, sweeps, and averaged normalized I-V (n = 4). All data was 
obtained using 5 mM Ba as charge carrier Currents were elicited every 4 sec by stepping 
to a test potential of 0 mV for 100 ms. Black bars in representative sweeps correspond to 
0.4 nA.   
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Figure 3-10 Summary of Inhibition by Oxo-M or AA of Cells Expressing Mutated or 
Chimeric CaVβ Isoforms. Here is shown percent inhibition of currents from HEK-M1 
cells expressing mutated or chimeric forms of CaVβ by (a) oxo-M or (b) AA. 
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CHAPTER IV 
 
 
 
 
DAG Lipase is Necessary for M1 
Muscarinic Inhibition of N-and L-, 
but not M-Current 
 86
Abstract 
 
M1 muscarinic receptors (M1R) affect cognition, learning and memory and are an 
important therapeutic target in the treatment of Alzheimer’s disease. M1R stimulation 
modulates currents through various types of voltage-gated ion channels, among them: 
KCNQ potassium channels (M-current) and both N- and L-type calcium channels (N- and 
L- current).  M1Rs couple to Gq/11 which activates phospholipase C (PLC).  Consequently 
PLC causes a depletion of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2).  
PtdIns(4,5)P2 hydrolysis during M1R stimulation suffices to elicit modulation of M-
current.  However, we’ve shown previously that events additional to PtdIns(4,5)P2 
hydrolysis are necessary for N- and L- current modulation; particularly the release of 
arachidonic acid (AA) after the activation of phospholipase A2 (PLA2).  Here we 
examined the effect of another AA liberating enzyme, diacylglycerol lipase (DAGL), on 
M-, N- and L-current modulation.  We documented the presence of DAGL in superior 
cervical ganglion (SCG) neurons, and then tested the selective DAG lipase inhibitor, 
RHC-80267, for its capacity to block M1R mediated inhibition of currents. We found 
while RHC-80267 has no effect on M-current modulation, it significantly reduces 
inhibition of both N- and L-currents.  Furthermore, RHC-80267 does not affect inhibition 
of N- or L- current elicited by exogenously applied AA.  These data corroborate our 
previous finding; indicating a divergence in signaling pathways for inhibition of M-
current versus N- or L- current. Moreover, these are the first data indicating a role for 
DAGL in modulation of N- and L-currents elicited by M1R stimulation.  
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Introduction 
The release of acetyl choline (ACh) in the central nervous system (CNS) is crucial 
for cognition, learning and memory (Woolf 1996).  ACh stimulates various muscarinic 
receptors which are encoded by five different genes (M1-M5; Caulfield and Birdsall 1998) 
all of which are expressed in the CNS (Levey et al., 1991; Wei et al., 1994).  The M1 
muscarinic receptor (M1R) is of particular interest, as it is the most prevalent subtype 
expressed in hippocampus and cortex regions of the brain associated with learning and 
memory (Levey et al., 1991; Wei et al., 1994). Also, severe cognitive and memory 
deficits occur in knockout mice lacking M1Rs (Anagnastoras et al. 2003).  Clinically the 
M1R is a therapeutic target for Alzheimer’s disease (AD).  At the present time the 
majority of drugs approved to treat AD act by increasing ACh at M1Rs (Ibach & Haen 
2004). 
M1Rs affect numerous neural functions including the modulation of voltage gated 
ion channels. In the early 1980s, M-current, a low threshold potassium current inhibited 
by muscarinic stimulation was identified in frog sympathetic neurons (Brown and Adams 
1980) and rat superior cervical ganglion (SCG) neurons (Constanti and Brown 1981).  
Since that time the signaling pathway that causes inhibition of M-current has been the 
subject of intense study (reviewed in Delmas and Brown, 2005). The present 
understanding is a depletion of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) 
during M1 stimulation causes a concentration gradient of PtdIns(4,5)P2 in the membrane, 
and inhibition occurs as PtdIns(4,5)P2 disengages and  diffuses from KCNQ channels. 
(Zhang et al. 2003; reviewed in Delmas and Brown 2005; Suh and Hille 2005) 
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M1R stimulation also inhibits certain voltage gated calcium currents. Since the 
activation of the receptor and time course of inhibition were equivalent for M-current and 
calcium currents, the mechanisms of inhibition were thought to be the same (Hille 1994).  
Recent reports indicating a depletion of PtdIns(4,5)P2 inhibits both P/Q- or N- currents, 
while increases in PtdIns(4,5)P2 concentration stabilizes P/Q- or N- currents (Wu et al., 
2002; Gamper et al., 2004) were seen as evidence that loss of PtdIns(4,5)P2 itself is both 
necessary and sufficient to cause inhibition of CaV2 channels (Suh and Hille, 2005a; 
Delmas et al., 2005; Delmas and Brown, 2005). 
However, our lab has presented evidence that downstream events after the 
metabolism of PtdIns(4,5)P2 are required for modulation of N- and L-currents. We have 
demonstrated stimulation of M1Rs by oxotremorine-M (Oxo-M) in SCG neurons 
produces a pattern of inhibition nearly identical to exogenous application of arachidonic 
acid (AA), inhibiting current at positive potentials and enhancing currents at negative 
potentials (Liu and Rittenhouse 2003a).  Absorption of AA with essentially fatty acid free 
bovine serum albumin (BSA) attenuates inhibition of N- or L- current by oxo-M.   We 
examined the role of phospholipase A2 (PLA2), an enzyme known to be instrumental in 
AA release. We found that PLA2 antagonists block M1R mediated inhibition of both N- 
and L-current in SCG neurons (Liu and Rittenhouse 2003a, Liu et al 2004).  Moreover, 
inhibition of L- but not M- is lost in cytoplasmic PLA2 knockout (cPLA2-/-) mice (Liu et 
al 2006).  
Since in many systems AA release depends on both PLA2 and diacylglycerol 
lipase (DAGL) (Ambs et al 1995; Caraway et al 2006, Liu 1999); we hypothesized 
DAGL would be essential for N- and L- current modulation by M1Rs. Here we present 
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evidence that DAGL is necessary for M1 mediated inhibition of N- and L- current.  We 
first verified the presence of DAGL in SCG and then examined its role in modulating M-, 
N- and L- currents.  We used a combination of pharmacological tools and 
electrophysiological protocols to isolate each of the currents. We then used potent and 
specific inhibitor RHC-80267 (RHC) to determine whether DAGL is necessary for 
current modulation.  We found RHC blocks N- and L- current modulation but not M-
current modulation. These data confirm our previous finding of diverging pathways for 
modulation of M- current and N- or L- current.   
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Results 
 
DAG lipase is present in SCG neurons 
To determine whether DAGL plays a role in current modulation we tested 
whether DAGL is present in SCG neurons.  We first determined that the message for 
DAGL is present in SCG by in situ hybridization.  A labeled oligonucleotide probe 
indicated substantial DAGLα mRNA in SCG neurons (Fig 4-1 a).  To control for non-
specific binding of the probe we repeated the experiment with a 250 fold excess of 
unlabeled oligonucleotide during hybridization (Fig 4-1 b).  These data confirm DAGLα 
is transcribed in SCG neurons. To determine whether or not DAGLα protein is expressed 
in SCG we performed immunoctochemistry with a DAGLα specific antibody (Bisogno et 
al 2003) and found strong DAGLα expression in SCG neurons (Fig 4-1 c,d).  
 
Pharmacological strategy for determining a role of DAGL in current inhibition   
Having established DAGL expression in SCG neurons we next designed a 
pharmacological approach shown in figure 4-2 to examine the role of DAGL in inhibition 
of M-, L-, and N- currents.  Stimulation of muscarinic receptors in SCG neurons results 
in inhibition that occurs through two separate pathways: 1) the fast pathway, mediated by 
M2 and M4 receptors, inhibits N-current; 2) the slow pathway, mediated by M1Rs, affects 
both N- and L- currents (Marrion et al. 1989; Mathie et al., 1992; Hille, 1994).  FPL and 
Nimodipine (NMN) were used to isolate L- or N-current and PTX was used to block the 
fast pathway. RHC-80267 [1,6-di(O-(carbamoyl)cyclohexanone oxime)hexane, (RHC)] 
is a potent and highly selective inhibitor of DAGL (Sutherland and Amin 1982).  As 
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shown, M-current inhibition should be unaffected by RHC as it results purely from a 
breakdown of PtdIns(4,5)P2.  Conversely, since both N- and L-current inhibition were 
shown to be sensitive to AA production we hypothesized antagonizing DAGL would 
attenuate Oxo-M induced inhibition of either current.   
 
RHC-80267 does not block inhibition of M-Current in neonate rat SCG neurons 
M-current is inhibited by a signaling pathway which involves the stimulation of 
M1Rs, (Marrion et al. 1989; Bernheim et al. 1992) the activation of Gαq (Haley et al. 
1998), the subsequent activation of PLC, the hydrolysis of PtdIns(4,5)P2 and its 
dissociation of PtdIns(4,5)P2  from the KCNQ potassium channel (Zhang et al., 2003; 
Ford et al., 2004).  A requirement for AA release in M-current inhibition has not been 
identified.  Moreover, RHC does not affect M-current inhibition in reconstitued KCNQ in 
tsA cells (Suh and Hille 2006).  Therefore, we anticipated M-current inhibition in SCG 
neurons would be the same in the presence or absence of the RHC.   M-current was 
measured in neonatal SCG neurons as previously described (Brown and Adams, 1980). 
Application of Oxo-M (10 µM) inhibited M-current by 54 ± 8 % (n = 4; Fig. 4-3 a,b,e). 
When neurons were exposed to RHC (20 µM) for at least 3 minutes Oxo-M inhibited M-
current by 48 ± 7 % (n =4; Fig. 4-3 c,d,e).  There was no significant difference in the 
percent change in current elicited by oxo-M between measurements taken in the absence 
or presence of RHC (p = 0.61, Fig. 4-3 e).  These data confirmed our hypothesis and 
corroborate the recently published results with reconstituted KCNQ in tsA cells (Suh and 
Hille 2005). More importantly, the inhibition of M-current in the presence of RHC shows 
the signaling pathway remains intact when DAG lipase is inhibited.  
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RHC-80267 blocks whole cell calcium current inhibition by M1R  
Our previous work showed AA mediates muscarinic inhibition and enhancement 
of whole-cell barium (Ba2+) currents in SCG neurons (Liu and Rittenhouse, 2003a).  
Therefore, we reasoned DAGL could be important for M1R mediated modulation of IBa in 
these same neurons.  To test this hypothesis we measured inhibition of whole-cell current 
using 20 mM Ba as the charge carrier in the absence and presence of RHC (20 µM).  
Cells were exposed to PTX (0.2 µg/ml) for five hours before recording whole-cell 
currents. This preincubation blocked downstream effects of M2 and M4 receptors, (Fig. 4-
2) leaving the M1 initiated pathway intact.   RHC was bath applied for at least three 
minutes before oxo-M. We found oxo-M elicited no change in current amplitude or 
kinetics (Fig. 4-2 a,b). Since AA and oxo-M elicit the same distinctive pattern of 
modulation in SCG neurons, enhancement at negative potentials and inhibition at positive 
potentials, we ran IVs before and 90 seconds after oxo-M application (Fig. 4-4 c). In the 
presence of RHC, oxo-M did not cause inhibition at any voltage (n =5).  There was a 
slight enhancement of current at -10 mV (+34 ± 14 %) but the change from control was 
not statistically significant (p = 0.08).   
 
RHC-80267 blocks L-current inhibition by Oxo-M 
The voltage gated calcium current of SCG is mainly N-current with a small 
percentage L-current (Plummer et al., 1989).  Since there was virtually no change in 
current elicited by oxo-M in whole cell currents as shown in the last experiment the data 
indicated both N- and L-current inhibition are sensitive to RHC and thus inhibition for 
both types of currents requires DAGL activity.  This would agree with our previous work 
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showing both N- and L-current inhibition are sensitive to AA release during M1R 
stimulation (Liu and Rittenhouse 2003a, Liu et al 2004, Liu et al 2006). Still to verify that 
both N- and L- currents are sensitive to RHC we used experimental protocol that tests the 
two types of current independently. Bath application of the L-channel agonist FPL (1 
µM) together with the voltage protocol shown in figure 4-5 produces a long lasting tail 
current consist entirely of L-current (Liu et al 2001).  The peak current observed during 
the initial depolarization is indicative of mainly N- current and is thus less sensitive to 
FPL. Accordingly, FPL typically caused a substantial increase in tail current and a slight 
increase in peak current (Fig. 4-5 a).  We compared inhibition of peak and tail currents 
by oxo-M as shown (Fig. 4-5 a,b).  Since PTX was not used in these experiments we 
used the inhibition of peak current, mainly due to fast pathway inhibition of N-current, as 
an internal control verifying the potency of the muscarinic agonist. Bath application of 
oxo-M (10 µM) inhibited peak current by 50.9 ± 8.4%. A 90 second exposure to RHC 
(25 µM) reduced peak current inhibition slightly to 40.2 ± 4.9%. It is expected that RHC 
does slightly attenuate peak current inhibition given that peak current inhibition is due to 
the total effect of M1, M2, and M4 receptors. However, this decrease is not significant 
since inhibition of N-current by M2 and M4 muscarinic receptors dominates the peak 
current inhibition.  Conversely, tail current in the absence of RHC is inhibited 43.0 ± 
4.0% by oxo-M while tail current in the presence of RHC inhibited only 9.0 ± 2.6% (Fig. 
4-5 a,b,e).   Thus, the inhibition of tail current is significantly reduced; signifying M1R 
mediated inhibition of L-current requires DAGL (Fig. 4-5 c). 
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RHC-80267 does not block L-current inhibition by AA 
So far we have shown that RHC blocks M1R mediated inhibition of whole-cell 
Ba2+ currents, which is made up of N- and L- current.  Both the M-current inhibition and 
N-current inhibition via the fast pathway occur in the presence of RHC, demonstrating 
that RHC does not interfere with signaling at the level of the muscarinic receptors. The 
lack of interference of M-current inhibition by RHC also demonstrates the M1R 
downstream effects of PLC activation and PtdIns(4,5)P2 hydrolysis are unperturbed.  The 
question remaining then is whether or not RHC effects slow pathway inhibition at the 
channel itself. 
The block of N- and L- current inhibition by RHC indicates AA production by 
DAGL is necessary.  Therefore, we hypothesized inhibition of N- or L- current should be 
recovered by exogenous application of AA. Since AA release occurs downstream of 
DAGL (Fig. 4-2) inhibition by AA should be unaffected by RHC. To test our hypothesis 
we applied AA (5 µM) to SCG neurons using both FPL and the tail protocol.  We found 
in the presence of RHC (25 µM) AA inhibits both peak and tail currents in a time frame 
consistent with previous experiments using AA (Fig. 4-6 a).  The amount of inhibition of 
peak current elicited by AA was the same in the absence (50.6 ± 3.0 %) or presence (41.4 
± 7.3 %) of RHC (Fig. 4-6 b).  Also, the amount of tail current inhibition was the same in 
the absence (41.5 ± 5.8 %) or presence (46.0 ± 9.4 %) of RHC (Fig. 4-6 b). As a final test 
of pharmacological interference of the slow pathway, we examined the inhibition of N-
current by AA in the presence of RHC and PTX.  We isolated N-current by bath 
application of nimodipine [NMN (1 µM)], an antagonist that minimizes L-current (Fig. 
4-2).  In the presence of RHC (25 µM) application of AA (5 µM) inhibited N-current by 
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56.4 ± 5.0 % (Fig. 4-7 a,b).  These data are comparable to previously reported levels of 
N-current inhibition elicited by AA (Liu et al 2001) and indicate inhibition of N- or L-
current by AA is unaffected by RHC.   
 
RHC blocks inhibition of N-current in a recombinant system 
Previously we found M1R stimulation inhibits reconstituted N-current in HEK 
cells with a stably transfected M1Rs (Peralta et al) transiently transfected with these N-
channel subunits: CaV2.2e, CaVβ3, and α2δ-1 (Chapter III).  Inhibition of N-current was 
54 ± 10% (n = 9; Figure 4-8 a,b).  We next reasoned that if DAG lipase is an important 
component of slow pathway RHC should also block M1R induced N-current inhibition in 
the recombinant system.  Therefore, we compared the inhibition of N-current elicited by 
M1R stimulation in the absence and presence of RHC.  Following a three minute 
application of RHC (20 µM), application of oxo-M (10 µM) elicited an initial large rapid 
inhibition of current as observed previously. However the inhibition subsided so that 
within three minutes there was virtually no inhibition left -4.8 ± 6.4% (n=6).  (Figure 4-8 
c,d).  Comparison of inhibition in the absence and presence of RHC showed block of 
inhibition to be significant (p ≤ 0.003). 
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Discussion 
Here we have shown DAGL as essential in mediating M1R mediated inhibition of 
N- and L- currents, but not M-current.  We first verified the presence of DAGLα in SCG 
neurons using both in situ hybridization and immunohistochemistry. Next, we showed 
inhibition of M-current is insensitive to RHC, indicating RHC does not block M1R 
signaling or downstream molecular mechanisms that lead to M-current inhibition.  
Conversely, RHC antagonizes inhibition of both N- and L- currents in neonatal SCG 
neurons indicating DAG lipase activity is necessary for inhibition. RHC does not 
interfere with current inhibition by AA. These data taken together indicate AA release 
during M1R stimulation is both necessary and sufficient for inhibition of N- or L-current.  
Our findings with native M-current corroborates the recent report that DAGL 
does not participate in M1R inhibition of activity of KCNQ channels expressed in tsA 
cells (Suh and Hille, 2006). Taken together, these findings support the general model that 
M-current inhibition results from a depletion of PtdIns(4,5)P2 and its subsequent 
dissociation from the KCNQ channels (reviewed in Suh and Hille, 2005a; Delmas and 
Brown, 2005).   
On the other hand, our data that RHC attenuates inhibition of N- and L- current 
seems to conflict a long held hypothesis that M- and N- current inhibition are mediated 
by a well conserved signaling pathway (Hille, 1994; Delmas and Brown 2005). However, 
two recent reports indicate a divergence in signaling pathways.  First, a series of 
palmitoylated cationic peptides designed to sequester PtdIns(4,5)P2 were effective in 
blocking M-current but not N-current inhibition (Robbins et al., 2006). Second, L-current 
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inhibition by M1R stimulation is absent in SCG neurons harvested from PLA2-/- mice, 
whereas M-current inhibition remains intact.   
Our data using exogenous AA corroborate other published observations using    
AA or its corresponding amide anandamide. For example, whole-cell currents from adult 
rat SCG neurons are enhanced at negative potentials and inhibited at positive potentials 
by anandamide (Guo and Ikeda 2004). In T-type channels, AA also simultaneously shifts 
activation towards negative potentials and increases steady state inactivation (Talavera et 
al 2004).  These data substantiate our observation that M1R stimulation and exogenous 
AA produce a similar, distinctive pattern of dual modulation of N-current.   
Our data identifying DAGL as an important component of slow pathway 
inhibition complements our previous work demonstrating a similar requirement for PLA2 
activity. Previously we reported inhibition of the AA producing PLA2 enzyme by 
oleyloxyethyl-phosphorylcholine (OPC) diminishes inhibition of N- current by oxo-M in 
SCG neurons (Liu and Rittenhouse 2003, Liu et al 2004).  These data have been openly 
questioned as OPC did not block the slow pathway the same cells but with different 
experimental conditions (Gamper et al., 2004).  We have endeavored to duplicate the 
experimental conditions in which OPC did not reduce inhibition.  When the using the 
perforated patch technique and solutions employed by Gamper and colleagues (2004), we 
found that a slightly longer preincubation with OPC was required in order to observe a 
loss of N-current inhibition (Liu, unpublished data).  Moreover, we identified a role for 
PLA2 in L-current inhibition using OPC, dialyzed antibodies specific for cPLA2, and 
neurons harvested from cPLA2-/- knockout mice.  Taken together these data indicate 
cPLA2 activation is necessary for L-current inhibition. 
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Our data do not diminish a proposed role for PtdIns(4,5)P2 in N-current inhibition 
but document a role for AA.  Our experimental conditions have yielded results indicting 
AA is both necessary and sufficient for slow pathway modulation (Liu et al 2003; Liu et 
al 2004; Liu et al., 2006). Other labs have yielded results which led to the conclusion 
PtdIns(4,5)P2 depletion is both necessary and sufficient for slow pathway modulation 
(Wu et al., 2002; Gamper et al., 2004). These data show that inhibition is not observed 
when PtdIns(4,5)P2 levels are kept high by exogenous application.  Likewise, 
sequestering of PtdIns(4,5)P2 with antibodies or cationic peptides results in inhibition.  
Recently, a model was proposed for modulation of voltage-gated potassium 
channels in which PtdIns(4,5)P2 depletion and AA formation exert bidirectional control 
of modulation (Oliver et al., 2004).  This study showed PtdIns(4,5)P2 stops the typical 
fast-inactivation of KV channels by binding to the N-terminal “ball” of the channel.  AA 
or anandamide reverses the effect of PtdIns(4,5)P2. The authors had determined a 
PtdIns(4,5)P2 binding site on the inactivation ball domain by mutating cationic residues, 
and had not proven a binding site for AA or anandamide, but postulated AA interferes 
with PtdIns(4,5)P2 through allosteric modification.  
Two opposing modulatory effects for PtdIns(4,5)P2 or AA on CaV2 channels have 
now been reported.  Wu and colleagues (2002) reported PtdIns(4,5)P2 sustains CaV2 
currents and causes an activation shift to positive potentials. Our lab has reported AA 
inhibits currents and causes an activation shift to negative potentials (Liu and Rittenhouse 
2003a, Liu et al 2001, Barrett et al 2001).  There may be some conserved mechanism by 
which channels respond to both PtdIns(4,5)P2 depletion and free AA.  Such a mechanism 
would seem an evolutionary advantage.  Since PtdIns(4,5)P2 depletion and AA formation 
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occur simultaneously sensitivity to both effects could make the channel more responsive 
to M1R stimulation. 
AA and PtdIns(4,5)P2 may act on distinct sites of the calcium channel α1 subunit 
and AA may interfere with a PtdIns(4,5)P2 effect via an allosteric mechanism as proposed 
for Kv channels. Alternatively, AA and PtdIns(4,5)P2 may compete at the same site.  This 
is a distinct possibility since AA occupies the sn-2 position in PtdIns(4,5)P2 molecules.  
A binding of PtdIns(4,5)P2 to the CaV2 subunit may involve a binding site for the 
arachidnoyl moiety present in all PtdIns(4,5)P2 molecules. If so, sufficient concentrations 
AA or anandamide could supplant PtdIns(4,5)P2 at this site. Then again both 
PtdIns(4,5)P2 and AA are bioactive molecules each with multiple effects, so either or 
both could act on the channel through another effector.  
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Figure 4-1. DAGLα message and protein is expressed in SCG neurons. (a) In situ 
hybridization of DAGLα in from adult rat SCG. Binding of labeled oligonucleotide 
shows considerable levels of DAGLα mRNA in neurons but minimal amounts in the fiber 
tract (FT).  (b) A competition control as described in the methods section. Low levels of 
nonspecific binding are observed over the entire section when a 250-fold excess of 
unlabelled oligonucleotides are added to the probe during hybridization. (c and d) 
Immunohistochemistry of adult rat SCG with DAGLα specific antibody shows strong 
labeling of protein in neurons but minimal in fiber tract.  Images represent duplicate 
experiments. 
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Figure 4-2.  Pharmacological strategy for dissecting DAG lipase from M1R induced 
pathways of current inhibition.  Muscarinic stimulation of SCG neurons by Oxo-M 
activates several pathways that inhibit ion channel activity.  M-current inhibition results 
from PLC induced depletion of PtdIns(4,5)P2 (Delmas and Brown 2005; Suh and Hille 
2005) and thus should be insensitive RHC-80267 (RHC).  Conversely, both L- and N- 
current inhibition are sensitive to AA production (Liu et al 2004; Liu et al 2006) and 
hypothetically may be sensitive to DAGL antagonism by RHC.  Inhibition of L- or N-
current should be restored with exogenous AA in the presence of RHC.  The L-channel 
agonist FPL 64176 (FPL) elicits long lasting tail currents consisting L-current thus 
highlighting L-current modulation and the L-channel antagonist nimodipine (NMN) 
diminishes L-current thus allowing observation of N-current modulation. Pertusis toxin 
(PTX) blocks a second pathway of N-current inhibition mediated by M2Rs or M4Rs.  
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Figure 4-3. M-Current inhibition by Oxo-M is unaffected by RHC.  M-current was 
measured in neonatal SCG neurons as previously described (Brown and Adams 1980). 
(a) Time course of current measured 400 ms after repolarization shows two applications 
of 10 µM Oxo-M. (b) Representative sweeps just prior to Oxo-M application (▬), 1 
minute after Oxo-M (▬) and 3 minutes after washing of Oxo-M (▬).  (b) RHC did not 
block inhibition of M-current. Time course and representative sweeps as described for a. 
(c). Summary of recordings comparing % inhibition of current occurring 1 minute after 
Oxo-M application in absence (n = 4) and presence (n =  4) of RHC (p=0.6). 
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 Figure 4-4. RHC blocks Oxo-M inhibition of the whole-cell current. Neonatal SCG 
neurons were pretreated with PTX for 5 hours to eliminate the fast pathway.  (a)  
Representative time course of whole cell Ba2+ does not show significant inhibition during 
application of Oxo-M (10 µM) in the presence of RHC. (b) Representative sweeps taken 
prior to Oxo-M (▬), 3 min after Oxo-M (▬) and 1 min after washout (▬).  (c)  Average 
IV data from PTX-treated SCG neurons. RHC blocks inhibition at positive potentials.  At 
-10 mV a slight enhancement remains although not statistically significant (p=0.08), n=5.   
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Figure 4-5. RHC attenuates Oxo-M inhibition of whole-cell L-type current. (a) 
Representative time course showing bath application of 25µM RHC blocks Oxo-M 
inhibition of tail currents in FPL treated SCG neurons, which is entirely made of L-type 
Ca2+ current. Conversely, Oxo-M still inhibits the peak current, due to membrane 
delimited inhibition of N-current. (b) Voltage protocol used to measure peak and tail 
currents with representative sweeps, from a holding potential of –90 mV the voltage is 
stepped to +10 mV for 20 milliseconds and then back to -40 mV. Peak current amplitudes 
were measured 15 ms after the start of the test pulse (C1). The long-lasting component of 
the tail current was measured approximately 13 ms following the test pulse (C2). The 
long-lasting component of the control tail current (in the absence of the L-type Ca2+ 
channel agonist) typically measured approximately ~5 pA in amplitude.  (c) Summary of 
the effects of Oxo-M on the currents in the absence of or in presence of RHC. N=4~5 
recordings. *P<0.05 
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Figure 4-6. RHC does not interfere with Inhibition of AA on whole-cell current. (a) 
Representative time course shows bath application of 25µM does not affect inhibition of 
peak current or the long-lasting component of the tail current by 5 µM AA on SCG 
neurons. (b) Summary of the effects of AA on the currents in the absence of or in 
presence of RHC. N=3~5 recordings. 
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Figure 4-5.  RHC Does not block the inhibition of whole-cell N- current by AA. (a) Bath 
application of RHC (25 µM) did not interrupt the effect of AA (5 µM) on N-type current 
in PTX-treated neonatal rat SCG neurons. Recordings were performed in the presence of 
1 µM NMN to block L-current (b) Summary of the effects of AA (5 µM) on the currents 
in presence of RHC in the bath solution. n=5 recordings. *p ≤ 0.05 
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Figure 4-8.  RHC blocks Oxo-M inhibition of N-type current in recombinant cells. HEK 
cells with a stably transfected M1 receptor (HEK-M1) were transiently transfected with 
N-channel subunits Cav2.2e, α2δ and Cav β3. Currents were recorded using 5 mM Ba2+ 
as the charge carrier. (a) time course of peak current before, during and after application 
of 10 µM Oxo-M shows transient inhibition followed by stable inhibition. (b) 
representative sweeps just prior to Oxo-M application (▬), 3 minutes after oxo-M (▬) 
and 1 minute after washing of oxo-M (▬).  RHC blocks stable inhibition in recombinant 
cells.  (c) Time course and (d) representative sweeps as described above (e) Summary of 
recordings comparing % inhibition of current occurring 3 minute after Oxo-M application 
in absence (n=9) and presence (n=6) of RHC **p<0.005. 
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CHAPTER V 
 
 
 
 
M1 Muscarinic Stimulation Blocks 
Fast Pathway Inhibition of N- Current 
117 
Abstract   
Direct binding of the Gβγ subunit of G-proteins to the α1 subunit of the N-type calcium 
channels (CaV2.2) inhibits their activity. During basal conditions Gβγ complexes bind to 
a portion of N-channels giving rise to tonic inhibition. Gβγ binding to CaV2,2 increases 
with stimulation of particular G-protein coupled receptors (GPCRs). This classical 
signaling cascade was originally referred to as membrane-delimited or voltage-dependent 
inhibition, but is now more commonly known as the fast pathway. Phosphorylation of 
CaV2.2 by protein kinase C (PKC) antagonizes Gβγ binding, thus reversing inhibition. 
Evidence for the role of PKC in current modulation has relied on phorbol esters to 
stimulate PKC. Comparable effects using neurotransmitters (NTs), predicted to activate 
PKC, have been elusive. M1 muscarinic receptors (M1Rs) activate PKC through a 
signaling pathway reliant on phospholipase C (PLC). However, the activation of PLC by 
M1Rs has multiple downstream effects, some of which may obscure the N-current 
modulation by PKC.  Specifically, activation of PLC participates in a diffusible second 
messenger pathway, also called the slow pathway that inhibits N-current.  Our lab found 
that bath application of either the specific DAG lipase inhibitor RHC-80267 (RHC), or 
the phospholipase A2 (PLA2) inhibitor oleoyloxyethyl phosphocholine (OPC) minimizes 
inhibition of N-current by the slow pathway. Both of these agents act by limiting the 
release of arachidonic acid (AA). Since neither RHC nor OPC is reported to inhibit PLC 
activity, I hypothesized either these agents could be used to block inhibition by M1Rs 
leaving PKC activation intact. An attenuation of fast pathway could be used as an 
indication of PKC phosphorylation. When this pharmacological strategy is employed in 
freshly dissociated neurons, M1R stimulation blocks inhibition normally elicited by the 
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membrane-delimited/fast pathway.  These data are consistent with activation of PKC and 
subsequent phosphorylation of the N-channel. 
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Introduction 
Calcium influx through N-type calcium channels (N-channels; CaV2.2) affects 
numerous neuronal functions including synaptic transmission (Hirning et al., 1988; 
Takahashi and Momiyama, 1993; Turner et al., 1993), regulation of neuronal excitability 
(Wisgirda and Dryer, 1992), control of intracellular biochemical processes, including 
enzyme activation (Rittenhouse and Zigmond, 1999)  and gene transcription (Brosenitsch 
and Katz, 2001; West et al., 2002).  The modulation of CaV2.2 activity by signaling 
cascades initiated by G-protein coupled receptors (GPCRs) is a key mechanism for fine 
tuning calcium influx (Elmslie 2003). 
N-channels are sensitive to inhibition via a signaling pathway now commonly 
referred to as the fast pathway, but also known as the membrane delimited pathway. This 
type of inhibition is characterized by direct binding of β and γ subunits of G-proteins to 
the CaV2.2 subunit (Herlitze et al., 1996; Ikeda, 1996). Under basal conditions a certain 
percentage of β and γ subunits of trimeric G-proteins bind to N-channels giving rise to 
what is known as tonic inhibition.  Prolonged depolarization relieves the inhibition as 
does challenging inhibition with a strong prepulse (Bean, 1989; Elmslie et al., 1990).  
Repetitive neuronal activity also reverses Gβγ inhibition of N-current, which may 
underlie short term plasticity (Brody et al., 1997; Brody and Yue, 2000).   
Pretreatment of neurons with protein kinase C (PKC) activating phorbol esters 
prevents fast pathway inhibition (Swartz, et al., 1993; Swartz, 1993). The 
phosphorylation of CaV2.2 by PKC at a region called the I-II linker appears to be the key 
molecular event in blocking membrane-delimited inhibition (Zamponi et al., 1997; 
DeWaard et al 1997, Hamid et al 1999).  Although it is has been studied extensively, 
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evidence of a role for PKC in N-current modulation has relied on phorbol esters to 
stimulate PKC.  Release of DAG typically activates PKC, which occurs when PtdInsP2 is 
hydrolyzed by phospholipase C (PLC).  Activation of PLC has multiple downstream 
effects, which may obscure N-current modulation by PKC.  Specifically, activation of 
PLC induces a diffusible second messenger that causes current inhibition.   
M1 muscarinic receptors (M1Rs) stimulate PKC (Caulfield and Birdsall 1998).  
Moreover M1 stimulation increases synaptic release by a mechanism reliant on PKC 
(Costa et al 1993).  Therefore, I examined the possibility that M1Rs modulate N-channels 
by activating PKC.  Here I report that M1R stimulation blocks N-current inhibition 
normally elicited by norepinepherine.  Moreover, the block of inhibition is consistent 
with activation of PKC. 
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Results 
Fast pathway inhibition by muscarinic receptors is transient in SCG neurons 
The working hypothesis for this work is that M1 stimulation of SCG neurons 
activates PKC, which subsequently phosphorylates N-channels. Recently our lab has 
found bath application of either the specific diacylglycerol (DAG) lipase inhibitor RHC-
80267 (RHC), or the (PLA2) inhibitor oleoyloxyethyl phosphocholine (OPC) minimizes 
inhibition of current by the diffusible second messenger pathway (Liu and Rittenhouse 
2003a; Liu et al 2004; Chapter IV). I hypothesized that by using this pharmacology I 
could block N-current inhibition by the diffusible second messenger during PLC 
stimulation revealing the effects of PKC on channel activity.   
N-channel phosphorylation should enhance current but normally inhibition of the 
slow pathway overshadows potentiation of N-current.  PKC stimulation could be 
observed if slow pathway inhibition was blocked downstream of PtdIns(4,5)P2 hydrolysis 
and DAG release. Since muscarinic stimulation of SCG neurons activates both slow and 
fast pathways of inhibition (Mathie et al., 1992), I first tried to use the muscarinic agonist 
oxotremoreine–methiodone (oxo-M) for both the stimulation of membrane-delimited 
inhibition and the activation of PKC (Fig 5-1a).  I hypothesized inhibition elicited by M2 
and M4 receptors would diminish as PKC, activated by M1 receptors, phosphorylated the 
channel, and thus displaced Gβγ subunits. With the slow pathway blocked by OPC, the 
activation of PKC would be observed as recovery of current. 
In freshly dissociated SCG neurons, whole-cell current was measured every 4sec 
by stepping to +10 mV for 100 msec from a holding potential of -90 mV. I found bath 
application of oxo-M (10 µM) elicits rapid inhibition marked by a change in whole-cell 
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kinetics to slowed activation, which diminishes over the course of several minutes with 
continued exposure to oxo-M (Fig 5 1 b,c). Both the rapid inhibition and slowed 
activation kinetics are indicative of membrane-delimited inhibition and the recovery of 
current amplitude and activation kinetics are both indicative of a dissociation of Gβγ 
from Cav2.2 (Barrett and Rittenhouse 2000).  Thus, these two effects could be interpreted 
as an indication of M1 stimulation of PKC.  Exposure to oxo-M for 30 seconds inhibited 
the current 30.8 ± 7.5% (n = 5), but after 3 minutes the current was inhibited by 0.64 ± 
18% vs. control.   
To determine whether the recovery of current was due to M1 stimulation, 
dissociated SCG neurons were preincubated with the potent and selective M1 inhibitor 
MT-7 (100 nM) for at least an hour at 37°C.  This toxin binds to and irreversibly blocks 
M1Rs (Adem and Karlsson 1997). In the presence of MT-7, current inhibition by the fast 
pathway still reversed over the course of several minutes (Fig 5-2 a, b).  Current was 
inhibited after 30 seconds by 47.1 ± 9.1% (n = 3), but by three minutes inhibition vs. 
control had diminished to 2.2 ± 4.8%.   
These findings suggested that the reversal of inhibition occurred independently of 
M1R signaling. In a separate control experiment I repeated the experiment with OPC to 
block slow pathway inhibition and the PKC inhibitor bisindolylmaleimide HCl I (BLM; 
100 nM) present in the bath.  Under these conditions, Oxo-M inhibited whole-cell current 
by 31.6 ± 9.8% (n = 5) after a  30 second exposure but after three minutes currents 
returned to control levels (-1.6 ± 9.5%).  Since the inhibited current recovered seemingly 
without stimulation of PKC or M1Rs, I concluded the original observation of transient N-
current inhibition was due to a mechanism such as receptor desensitization. M2Rs are 
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known to desensitize in a time frame of seconds to minutes (Hosey et al 1995). 
Therefore, I had to reassess the pharmacological strategy for maintaining fast pathway 
inhibition of N-current. 
 
Norepinepherine elicits a steady inhibition of current via the fast pathway 
I next sought a neurotransmitter or agonist that could elicit stable inhibition over the 
course of several minutes, so that changes in inhibition could be attributable to a 
downstream effect of M1Rs. In SCG neurons norepinepherine (NE) binds to α2 adrenergic 
receptors, stimulating membrane-delimited inhibition of N-current but not slow pathway 
inhibition (Mathie et al 1992).  Since membrane-delimited inhibition is voltage 
dependent, I used a prepulse protocol to examine N-current inhibition apart from 
rundown.  The prepulse protocol (Elmslie et al., 1990) utilizes a strong depolarizing step 
to +80 mV (100 msec); a brief return to -90 mV (5 msec); followed by a test pulse to +10 
mV. The strong depolarizing step reverses inhibition elicited by membrane-delimited 
inhibition (Elmslie et al., 1990).  Currents elicited after the depolarization are referred to 
as “facilitated”. Whole-cell current was measured every 4 sec at +10 mV from a holding 
potential of -90 mV.  The prepulse protocol was used for every other measurement so as 
to alternate between facilitated and unfacilitated whole-cell current measurements. The 
representative time course shown in (Fig 5-2 a,b) is typical with application of NE. NE 
(10 µM) caused both a large voltage-dependent and small voltage-independent inhibition; 
however voltage-independent inhibition was transient while voltage-dependent inhibition 
was stable for several minutes.  The stable inhibition by NE indicated a continuous 
association of Gβγ with the channel. Thus changes in NE induced inhibition could be 
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interpreted as a dissociation of Gβγ from the channel presumably due to PKC activation.  
We previously showed that the M2R antagonist methoctramine (METH) blocks M2Rs 
thereby eliminating fast pathway inhibition by oxo-M in SCG neurons (Liu and 
Rittenhouse 2003a).  Thus hypothetically, oxo-M could be used to stimulate M1Rs 
without causing membrane-delimited inhibition and if the downstream effects of M1Rs 
that cause further inhibition were blocked, PKC stimulation should be unaffected (Fig. 5-
2 c).  
PKC stimulation elicited with the phorbol ester phorbol 12-myristate 13-acetate 
(PMA) is reported to block inhibition by NE (Swartz, 1993).  Therefore, PMA was used 
to stimulate PKC effect with which the oxo-M effect could be compared. Application of 
NE (10 µM) caused a strong voltage-dependent inhibition as previously described 
(Kammermeier et al 2000) but also a slight voltage independent inhibition (Fig. 5-4 a). 
As shown the application of NE before PMA (500 nM) elicited a large voltage-dependent 
inhibition but a five minute exposure to PMA blocked any facilitation of current by a 
prepulse (Fig. 5-4 a). These data agree with previous studies that PKC activation and 
prepulse facilitation are equivalent in reversing membrane-delimited inhibition (Barrett 
and Rittenhouse 2000).  
Since membrane-delimited inhibition is voltage-sensitive, prepulse facilitation 
was used as a determination of Gβγ binding. Facilitation is the percent increase in current 
which occurs after the +80 mV depolarization (see methods).  During the first application 
of NE prepulse facilitation was 103 ± 31 % (n = 4). A five minute exposure to PMA 
reduced the prepulse facilitation to 26 ± 14 % (Fig. 5-4 c).  Changes in kinetics were 
determined by measuring the time to peak current during the 100 millisecond test pulse. 
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Membrane delimited inhibition causes slow activation of current, thus the time to peak is 
delayed. Conversely, relief of inhibition, either by a strong depolarization or by PKC 
phosphorylation, decreases the time to peak. During NE, the time to peak was 65 ± 10 ms 
(n = 4). After a five minute exposure to PMA and the time to peak elicited by NE was 17 
± 6 ms. (Fig. 5-4 d).  
 
Oxo-M blocks inhibition by NE 
To stimulate PKC via M1Rs, I tried different concentrations of oxo-M in 
conjunction with METH (100 nM) and either OPC (10 µM) or RHC (20 µM). 10 µM 
oxo-M had been previously shown to be sufficient to elicit both fast and slow pathway 
inhibition in SCG neurons (Liu and Rittenhouse 2003a).  However this concentration of 
oxo-M did not block the inhibition of NE (Fig. 5-5 a,b).  Therefore the concentration of 
oxo-M was increased. Previously Liwang in our lab reported 30 µM oxo-M is necessary 
to elicit maximal inhibition of N-current via the slow pathway (Liu and Rittenhouse 
2003b). Since the slow pathway and PKC activation are both hypothetically downstream 
of M1Rs 30 µM oxo-M might also be necessary to elicit PKC activation.  Accordingly, a 
three minute exposure to oxo-M (30 µM) dramatically blocked inhibition by NE (Fig. 5-5 
c,d).  As shown in the representative time course in (Fig. 5-5 c), there was a brief spike of 
inhibition which subsided.  This brief spike of inhibition may not be the result of Gβγ 
inhibition. In the previous experiments with NE and prepulses NE elicited a small 
voltage-independent inhibition (see Fig. 5-4 a and Fig 5-3 a). The voltage–independent 
inhibition has been ascribed to incomplete dissociation of Gβγ by the strong 
depolarization (Kammermeier, et al 2000).  However I found the voltage-independent 
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and voltage-dependent inhibition caused by NE to be fundamentally different. First, the 
voltage-independent inhibition was transient over the course of a few minutes. Second, 
after a five minute exposure to PMA the voltage-dependent inhibition was lost, but the 
voltage-independent inhibition recurred (Fig. 5-3 a) Therefore it appears under the 
recording conditions NE elicits two types of inhibition. To avoid spurious effects of 
inhibition not due to Gβγ, inhibition of current was measured 25 seconds after application 
of NE.  Following a three minute exposure to oxo-M (30 µM) in the presence of RHC (20 
µM) and METH (100 nM), NE (10 µM) elicited an inhibition of 8.4 ± 4.4 % (n = 5).   
To ensure the block of inhibition was not due to non-specific effects of the 
combination of RHC and METH two separate control experiments were run. First, the 
inhibition of current by NE (10 µM) was measured when RHC (20 µM) and METH (100 
nM) were in the bath but no oxo-M exposure.  Under these conditions NE inhibited 
current 39 ± 4.3 % (n = 8). Second, the inhibition by NE (10 µM) was measured without 
any of other aforementioned drugs. Under these conditions NE inhibited current 32 ± 2.8 
% (n = 30).  Inhibition by NE after 30 µM oxo-M was significantly different from either 
control condition (p < 0.001). 
To see if the kinetic changes were blocked by oxo-M the time to peak was 
determined for each of the conditions described above.  Under control conditions with out 
any other drugs in the bath NE causes the time to peak to shift on average to 76 ± 4.2 
msec (n = 30),  whereas in the experimental conditions using oxo-M the time to peak was 
26 ± 4.5 msec (n = 5) a significant change (p < 0.001).  However, after exposure to RHC 
and METH, without oxo-M the time to peak was variable, so that the average was 47 ± 
10 msec (n = 8).  These data suggest the kinetic and amplitude changes may be separable 
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effects, the kinetic changes being somewhat sensitive to the presence of RHC and 
METH.  Pretreatment with oxo-M elicited a consistent block of the slowed activation, 
coupled with the dramatic block of inhibition suggested that PKC had been stimulated. 
Having established a concentration of oxo-M which mimicked PKC activation 
experiments were set up with the prepulse protocol similar to the ones described earlier to 
test activation of PKC by PMA.  Breifly, during whole cell recordings from SCG 
neurons, NE (10 µM) was applied to before and after a three minute exposure to 30 µM 
oxo-M. RHC (20 µM) and METH (100 nM) were present in the bath solutions during the 
entire experiment (Fig.5-6 a). 
  As before Gβγ inhibition was indicated by increased facilitation and the time to 
peak shifted toward the end of the 100 msec pulse. These parameters were calculated for 
cells exposed to NE before and after oxo-M. The prepulse facilitation caused by NE was 
reduced from 91 ± 16 % before oxo-M to 47 ± 24 % (n = 6).   Also the time to peak 
during NE stimulation was shortened from 56 ± 9.7 msec to 24 ± 9.3 msec.  These data 
further suggested an activation of PKC. 
 
PKC inhibitors do not stop loss of NE modulation 
To show the loss of NE induced inhibition was truly due to PKC activation, the 
next step was to repeat the experiment and block the effect with PKC inhibitors. First a 
pharmacological strategy was tried.  In our lab, BLM had been used successfully to block 
PKC activation of PMA (Barrett and Rittenhouse 2000). For those reported experiments 
BLM (100 nM) had been dissolved in dimethyl sulfoxide (DMSO).  DMSO because it 
has non-specific effects, and there was some evidence that DMSO interferes with M1Rs 
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in our cell prep and recording conditions (comm. Liwang Liu).  Therefore the water-
soluble, hydrochloride salt of BLM was used in an attempt to block the PKC effect.  The 
same protocol as before with prepulses, two separate applications of NE (10 µM) 
separated by an application of oxo-M (30 µM), was used in conjunction with RHC (20 
µM), METH (100 nM) and with the addition of BLM (100 nM; Fig 5-7 a). Under these 
conditions during the first application of NE the facilitation was 148 ± 14 % after a three 
minute application of oxo-M facilitation was 58 ± 7 % (n=4; Fig 5-7 b). The time to peak 
during the first application of NE was 84 ± 3.3 msec, and 38 ± 10 msec during the second 
application of NE (Fig 5-7 c). These data did not indicate addition of BLM blocked the 
apparent PKC effect. 
The experiment in which 30 µM but not 10 µM oxo-M blocked NE effects 
indicated there was a specific effect of oxo-M, but paired compared comparisons on the 
same cell requires holding cells much longer. Also, the water soluble form of BLM had 
not been characterized in our lab. Therefore several possibilities arose that could explain 
why there was not a loss of NE induced modulation. First holding a cell in the whole-cell 
configuration for extended periods of time could result in dialysis of factors necessary for 
inhibition by NE. Second, a longer exposure to the pharmacological agents could 
possibly cause non-specific effects. Third, it was possible that the water-soluble form of 
BLM required was not as effective as the hydrophobic form used earlier and thus higher 
concentrations of the inhibitor could be necessary. Experiments were set up to determine 
which if any of these effects contributed to the loss of NE induced modulation.  
First, to determine if prolonged whole-cell recordings were dialyzing essential 
factors out of the cell, paired applications of NE separated by a three minute wash with 
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bath solution without any drug were compared.  There were no significant differences 
between the two applications of NE (data not shown).  Therefore, the loss of NE effect 
was not caused by dialysis of some factor out of the neuron during the whole-cell 
measurement.  Next, a similar experiment was conducted examining the effect of two 
applications of NE separated by a three minute wash, with METH and RHC in the bath 
during the entire recording. Under these conditions prepulse facilitation during NE 
application was significantly reduced. These data indicate prolonged exposure to METH 
and RHC might also induce some PKC activity.  A long exposure to RHC might inhibit 
basal activity of DAG lipase, increase DAG concentrations and thereby activate PKC if 
given a sufficient period of time. If the loss of NE induced modulation was due to PKC 
activation by prolonged exposure to RHC or a shorter exposure to oxo-M then either 
effect should be blocked by a sufficiently effective PKC inhibitor. 
Therefore, the concentration of BLM was increased and retested for its capacity to 
block PKC activity induced by PMA.  500 nM BLM was included in both the bath and 
pipette solutions.  The IC50 for BLM is reported to be 3-70 nM (Toullec et al 1991).  In 
control conditions facilitation of current induced by NE (10 µM) was 87 ± 12 %, but after 
a five minute exposure to PMA, facilitation of current induced by NE diminished to 14 ± 
5.3 % (n=12).  When BLM (500 nM) was included in the solutions initial facilitation 
during NE was 86 ± 19 %, and after PMA exposure the facilitation during NE was 56 ± 
13 % (n = 7; Fig 5-8 a). The kinetic shift was also affected.  Under control conditions the 
time to peak elicited by NE went from 73 ± 8.2 msec to 7.9 ± 0.7 msec before and after 
PMA.  With BLM on board the time to peak went from 61 ± 13 msec to 39 ± 13 msec 
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(Fig 5-8 b).  These data indicate the presence of 500 nM BLM (approximately ten times 
the IC50) greatly attenuates but does not eliminate PMA’s capacity to block effects of NE. 
 
Inhibition of PKCε attenuates PKC effect 
Since BLM did not completely block the apparent effect of PKC other inhibitors 
of PKC were sought.  It is reported that PKCε is bound to the carboxy-terminus of 
CaV2.2 (Maeno-Hikichi et al., 2003). Moreover, PKC modulation of whole-cell calcium 
currents in hippocampal neurons is completely disrupted by dialysis of 10 µM PKCε 
translocation inhibiting peptide (PKCε-TIP).  Therefore, whole cell currents from SCG 
neurons were measured with 10 µM PKCε-TIP in the pipette using paired applications of 
NE (10 µM) to stimulate membrane delimited inhibition and PMA 500 nM to stimulate 
PKC.  With 10 µM PKCε-TIP in the pipette facilitation during NE application went from 
97 ± 9.4 % before PMA to 33 ± 9.2 % after PMA (n=3).  This concentration did not 
eliminate NE induced changes in current, so the concentration was and retested.  When 
20 µM PKCε-TIP was in the pipette the facilitation went from 102 ± 23 % before PMA to 
72 ± 28 % after PMA (n=3). Since facilitation recurred robustly this was a considerable 
improvement in blocking the PKC effect.   The higher concentration of PKCε-TIP also 
had a significant effect on kinetic changes.  When 10 µM PKCε-TIP was included in the 
pipette time to peak elicited by NE went from 86 ± 3.6 msec before PMA, to 22 ± 6.7 
msec after PMA. Conversely, when 20 µM PKCε-TIP was included in the pipette time to 
peak went from 73 ±14 msec before PMA to 40 ± 25 msec after PMA.   
 
 
131 
Discussion 
Here I have presented evidence of a muscarinic agonist resulting in an attenuation 
of membrane-delimited inhibition. I used a pharmacological approach to block the 
diffusible second messenger pathway, to observe a reversal of G-protein mediated N-
current inhibition.  Initially, I found that recovery of membrane-delimited current 
inhibition, induced by the classic muscarinic agonist Oxo-M, is not caused by PKC 
activation but is more likely evidence of M2R receptor desensitization.  Still, 30 µM Oxo-
M, presumably through M1Rs, successfully blocked NE-induced N-current inhibition by 
the membrane-delimited pathway when the M2R antagonist, METH and the DAG lipase 
inhibitor, RHC-80267 were included in the bath.   
The pharmacological strategy using 30 µM oxo-M blocked both the changes in 
current amplitude and current kinetics normally elicited by NE.  Moreover, the 
pharmacological strategy produced results similar to the PKC activating phorbol ester 
PMA.  Therefore, these data are consistent with an activation of PKC.  I found the 
application of the PKC inhibitor BLM did not reverse the action of 30 µM oxo-M.  
However, I found the apparent affects of PKC activation by PMA were also resistant to 
block with BLM.   
The experiments I presented here were based on a combination standard 
electrophysiological techniques and pharmacological agents. Each of the drugs I used in 
this study has been used previously in other studies. However, a combination of drugs 
can produce non-specific effects.  For example I found the combination of OPC and 
METH destabilized the membranes of neurons during whole-cell current measurements.  
Also, RHC and METH together reduced the changes in kinetics produced by NE, and 
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when applied for long periods of time reduced the amount of inhibition elicited by NE. 
Therefore, I’ve taken care to run proper controls.  I found a combination of RHC and 
METH partially blocked inhibition of N-current by NE indicating a possible increase in 
basal PKC activity. However, the PKC activity elicited by 30 µM oxo-M is more robust. 
These data are consistent with phosphorylation of N-channels by PKC activated by 
M1Rs. 
In the same way reversal of Gβγ induced inhibition by neuronal activity 
constitutes a putative mechanism for short term plasticity (Brody and Yue 2000), the 
activation of PKC to attenuate tonic inhibition of calcium current and block further 
inhibition elicited by GPCRs may also constitute a mechanism for short term plasticity.  
Therefore identification of the receptors which activate PKC to phosphorylate channels is 
a key to understanding basic neural function.  Not surprisingly, attempts to discern the 
neuronal receptors that induce phosphorylation of CaV2 channels via PKC comprise an 
active field of research.  
Recently it was reported that M1Rs do not cause phosphorylation of CaV2.2 
channels so as to block fast pathway inhibition (Kamatchi et al., 2004).  In this study 
potentiation of current in oocytes expressing M1Rs and either CaV2.2 or CaV2.3 was 
gauged during muscarinic stimulation or PMA application. The authors found that while 
PMA potentiates CaV2.2 current, M1 stimulation does not. Conversely both M1 
stimulation and PMA potentiate CaV2.3 current. The authors of this study concluded that 
specific residues of the II-III linker of CaV2.3 are phosphorylated by M1R stimulation but 
the PKC consensus sites on the I-II linker of CaV2.2 and CaV2.3, which have been 
implicated in the block of Gβγ binding (Hamid et al., 1999) are not phosphorylated 
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during M1R stimulation.  They came to the conclusion that M1 stimulation activates 
conventional forms of PKC (α, βI, βII, and γ) whereas other receptors stimulate novel 
PKC isoforms such as PKCε.   
There are several reasons for the disagreement in findings.  First is the use of 
oocytes in the alternate study.  Although oocytes have been used well to elucidate many 
aspects of channel function, they may not contain all the necessary signaling components 
to be applicable to neuronal preps.  The second possible reason for the discrepancy is the 
use of RHC to block the slow pathway.  If DAG lipase is normally active during M1 
stimulation then DAG may be to low to activate PKC. A third possibility is that 
muscarinic stimulation interferes with NE signaling through a mechanism that does not 
require PKC. A fourth possibility for the disagreement is that they may not have had the 
right conditions in their expression system to observe potentiation.  Enhancement of 
current by PKC requires tonic inhibition due to Gβγ bound to the channel (Swartz et al., 
1993; Barrett and Rittenhouse 2000). The expression of certain CaVβ subunits in 
recombinant systems can adversely affect Gβγ binding (Roche et al., 1995; Roche and 
Treistman 1998). If Kamatchi and colleagues did not have sufficient tonic inhibition then 
phosphorylation could occur without any change in current amplitude or kinetics (Barrett 
and Rittenhouse 2000). 
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Figure 5-1. Muscarinic activated membrane-delimited inhibition is transient in SCG 
neurons (a) Shown is a pharmacological strategy to dissect PKC activation from other 
pathways.  Muscarinic activated fast pathway inhibition can be antagonized by activation 
of PKC. Hypothetically, PKC may be activated by M1 stimulation.  Fast pathway is 
activated through M2 and M4 receptors while PKC is activated by M1 receptors.  Typical 
slow pathway inhibition of voltage gated calcium currents is blocked by PLA2 antagonist 
OPC. (b)  Representative time course of whole-cell current is transiently inhibited by 
oxo-M in the presence of OPC. (c) Representative sweeps take from time course show 
slowed activation kinetics typical of membrane delimited inhibition recovering within 
several minutes. For the representative time course and all subsequent time courses 
current was measured 7 msec after the start of the test pulse. 
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Figure 5-2. Membrane–delimited inhibition is transient without M1 simulation. (a) time 
course shows unfacilitated (●) and facilitated (■) whole-cell currents measured in the 
presence of MT-7. (b) representative sweeps taken prior to (0 s) application of oxo-M, 30 
seconds after oxo-M application and 3 minutes after oxo-M.  Each representative sweep 
depicts an overlay of an unfacilitated (▬) and facilitated (▬) recording taken 4 seconds 
apart (c) summary of inhibition elicited by oxo-M at 30 seconds and 3 minutes after onset 
of application, in the presence of OPC, MT-7 or OPC and BLM 
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Figure 5-3. NE causes stable inhibition of whole-cell currents. (a) time course shows 
unfacilitated (●) and facilitated (■) whole-cell currents measured before and after 
application of 10 µM NE (b) representative sweeps of unfacilitated (▬) and facilitated 
(▬) recordings taken 4 seconds apart taken prior to (0 s) application of NE, 30 seconds 
after oxo-M application and 3 minutes after NE. (c) revised pharmacological strategy for 
dissecting PKC from M1 stimulated pathways in SCG neurons. Fast pathway inhibition 
activated by M2 receptors can be blocked with 100 nM METH while slow pathway 
inhibition of M1 receptors can be blocked with 20 µM RHC. Fast pathway inhibition can 
be induced with 10 µM NE after PKC activation.   
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Figure 5-4. PMA blocks voltage-dependent inhibition elicited by NE. (a) representative 
time course shows unfacilitated (●) and facilitated (■) whole-cell currents measured in 
the before and after two distinct applications of 10 µM NE separated by a five minute 
application of 500 nM PMA (b) representative sweeps taken prior to (control) application 
of NE, 30 seconds after the first application of NE (NE) and 30 seconds after the second 
application of NE (NE post PMA) (c) Inhibition by NE as represented by prepulse 
facilitation elicited 30 seconds after NE application before (control) and after PMA 
(PMA). (d) Change in kinetics of facilitated and unfacilitated currents as represented by 
time to peak elicited by NE before (control) and after PMA (PMA). 
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Figure 5-5. 30 µM Oxo-m blocks inhibition by NE. (a) representative time course of 
whole-cell recordings in which M1 receptors were stimulated for three minutes by 10 µM 
oxo-M in the presence of 100 nM METH and 20 µM RHC.  Subsequently α2 receptors 
were stimulated with 10 µM NE (b) representative sweeps taken prior to (▬) application 
of NE, and 30 seconds after NE (▬) application. (c) The same experiment as described 
for a and b with the substitution of 30 µM oxo-M.  (d) Representative sweeps taken prior 
to (▬) application of NE, and 30 seconds after NE (▬) application. (e) Inhibition by NE 
was calculated as a percent change of current that occurred as a result of NE by 
comparing current amplitude measurements prior to and 30 seconds after NE application.  
Shown are averaged determinations for comparison of currents measured without METH, 
RHC or oxo-M, (control), with RHC and METH, but no oxo-M, and 30 µM oxo-M, with 
RHC and METH  (f)  Change in kinetics of as represented by time to peak elicited by NE 
under same conditions as described for e. 
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Figure 5-6. 30 µM oxo-m block of inhibition is consistent with PKC activation. (a) 
representative time course shows unfacilitated (●) and facilitated (■) whole-cell currents 
measured in the before and after two distinct applications of 10 µM NE separated by a 
three minute application of 30 µM oxo-m, in the presence of METH and RHC as 
described earlier  (b) representative sweeps of unfacilitated (▬) and facilitated (▬) 
recordings taken prior to (left) application of NE, 30 seconds after the first application of 
NE (center) and 30 seconds after the second application of NE (right) (c) Inhibition by 
NE as represented by prepulse facilitation elicited 30 seconds after NE application before 
(control) and after oxo-M (Oxo-M). (d) Change in kinetics of facilitated and unfacilitated 
currents as represented by time to peak elicited by NE before (control) and after oxo-M 
(oxo-M). 
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Figure 5-7. 100 nM BLM does not block effect of 30 µM oxo-M pretreatment.  (a) 
representative time course shows unfacilitated (●) and facilitated (■) whole-cell currents 
measured in the before and after two distinct applications of 10 µM NE separated by a 
three minute application of 30 µM oxo-m, in the presence of METH and RHC as 
described in the previous figure with the addition of 100 nM BLM to the bath solution. 
(b) Inhibition by NE as represented by prepulse facilitation elicited 30 seconds after NE 
application before (pre Oxo-M) and after oxo-M (post Oxo-M). (d) Change in kinetics of 
facilitated and unfacilitated currents as represented by time to peak elicited by NE before 
(pre Oxo-M) and after oxo-M (post Oxo-M). 
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 Figure 5-8. 500 nM BLM partially blocks effect of 500 nM PMA pretreatment.  (a) 
summary of inhibition elicited by NE as determined by % facilitation before and after a 
three minute application of 500 nM PMA. Shown are the data from two sets of 
experiments one without BLM (■) the other with 500 nM BLM in both bath and pipette 
solutions (■). (b) time to peak measurements taken from the same sets of experiments. 
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Figure 5-9. 20 µM PKCε-TIP partially blocks effect of 500 nM PMA pretreatment.  (a) 
summary of inhibition elicited by NE as determined by % facilitation before and after a 
three minute application of 500 nM PMA. Shown are the data from two sets of 
experiments one with 10 µM PKCε-TIP in the pipette solution (■) the other with 20 µM 
PKCε-TIP in the pipette solutions (□). (b) time to peak measurements taken from the 
same sets of experiments. 
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CHAPTER VI 
 
  
 
 
General Discussion 
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In this thesis I have explored the modulation of N-channels by M1 muscarinic 
receptors.  M1Rs have multiple downstream effects, several of which modulate CaV2.2.  
To study various effects independently of each other I took two approaches; a 
pharmacological approach, blocking various M1R induced pathways in neurons; and a 
reductionist approach, expressing CaV2.2e in non-neuronal cells with M1Rs.  Both of 
these approaches yielded novel results expanding the understanding of M1 modulation of 
N-current. Here I’ve shown the expression of CaVβ subunit can toggle M1R muscarinic 
modulation between enhancement and inhibition of N-current (chapter III). I’ve 
identified DAG lipase as a previously unrecognized component of slow pathway 
inhibition (chapter IV).  Finally, I’ve demonstrated M1 stimulation attenuates N-current 
inhibition typically induced by Gβγ binding (chapter V).   
 
AA is a component of the slow pathway 
Each investigation of M1 modulation of N-current that I’ve described is shaped by 
a central premise that AA serves a vital role in the slow pathway.  This premise is based 
on previous work published by other members of my lab (Liu et al. 2006, 2004; Liu and 
Rittenhouse 2003a). The investigations I’ve reported here corroborate those initial 
findings and provide further evidence of AA’s importance in the slow pathway.  In a 
recombinant system using wild type N-channel subunits, application of AA reproduces 
every effect of M1R stimulation by Oxo-M, strongly suggesting AA mediates N-channel 
modulation. These effects are: inhibition of current with CaVβ1b, CaVβ3, or CaVβ4 
enhancement of current with CaVβ2a (Chapter III).  Moreover, the discovery that DAG 
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lipase activity is required for slow pathway inhibition implicates a role for AA (Chapter 
IV).   
The importance of AA in the slow pathway is at present controversial. A model 
for N-current modulation incorporating AA as an essential component represents a 
departure from a model established for M-current inhibition, in which PtdIns(4,5)P2 
depletion suffices to cause inhibition (Delmas and Brown 2005). Also, evidence for a 
similar model for calcium channel inhibition based on PtdIns(4,5)P2 depletion has been 
accumulating (Suh and Hille 2005).   
It had been postulated that the underlying mechanism for M- and N-current 
inhibition would prove to be the same, given a similar progression of inhibition during 
M1R stimulation (Hille 1994). However, our lab has presented evidence that the 
modulating pathways for M- and L- current are not the same (Liu et al., 2006), 
specifically while L-current inhibition requires cPLA2 activation M-current inhibition 
does not. Therefore, when examining the role of DAGL in N- and L- current modulation, 
I also tested M-current to show the established model is not in question, that is a block of 
DAGL does not affect M-current inhibition (Chapter IV).   
My findings together with previous reports generated by our lab indicate a model 
in which PtdIns(4,5)P2 depletion is the sole mechanism of inhibition is incomplete.  If N-
channels are sensitive to both PtdIns(4,5)P2 depletion and AA formation, then 
experimental conditions might show either to be both necessary and sufficient for 
inhibition.  It’s possible that sufficient amounts of exogenously applied PtdIns(4,5)P2 
during M1 stimulation blocks inhibition, and sufficient amounts of exogenously applied 
AA induces inhibition in vitro, but the amounts used to elicit these effects are greater than 
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what may be generated under normal physiological conditions (Fig. 6-1). Although at the 
present time it is not possible to accurately gauge the concentration of PtdIns(4,5)P2 or 
AA at the channel, at any particular point in time. 
Since PtdIns(4,5)P2 depletion and AA formation occur simultaneously, sensitivity 
to both effects would make the calcium channel more responsive to M1R stimulation, as 
has been proposed for a type of potassium channels (Oliver et al., 2004).   Wu and 
colleagues (2002) reported PtdIns(4,5)P2 sustains CaV2 currents and causes an activation 
shift to positive potentials. While our lab reported AA inhibits currents and causes an 
activation shift to negative potentials (Liu and Rittenhouse, 2003a; Liu et al., 2001; 
Barrett et al., 2001).  In both types of modulation PtdIns(4,5)P2 and AA act in opposite 
directions.  Each lab reported that the two types of modulation were unconnected 
molecular effects occurring at distinct sites on the channel.  Although no binding site for 
PtdIns(4,5)P2 or AA has been determined, there is agreement that the site of inhibition is 
inside the plasma membrane (Wu et al., 2002; Barrett et al., 2001).  This is supported by 
my discovery that the cytoplasmic CaVβ2a subunit blocks inhibition without affecting the 
voltage shift in gating (chapter III).   
Finally it must be noted that the inclusion of AA in a pathway of modulation for 
calcium currents has implications in intercellular signaling.  Unlike PtdIns(4,5)P2 , AA 
can  leave the plasma membrane and diffuse to an adjacent cell.  In fact, AA has been 
implicated as a retrograde messenger for both long term potentiation (Williams et al., 
1989) and long term depression (Bolshakov and Siegelbaun, 1995), two neural 
mechanisms thought to be the underpinnings of learning.  Thus, for example, M1 
stimulation in a postsynaptic cell could elicit release of AA modulating N-current in the 
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presynaptic cell.  Moreover the modulation by AA could be potentiation or inhibition 
depending on the channel composition. 
 
CaVβ expression has extensive effects 
My finding, that the expression of Cavβ subunit can toggle M1R muscarinic 
modulation between enhancement and inhibition of N-current was totally unexpected and 
may have far reaching consequences.  The discovery that switching the CaVβ subunit of 
N-channels directs modulation reveals a physiological mechanism by which modulatory 
effects can occur independently at different channels.  The initial discovery of 
enhancement by AA was interesting (Liu et al 2001; Barrett et al 2001) and since it 
caused cells to become more sensitive to small depolarizations such as EPSPs, it 
suggested a role for post-synaptic modulation of N-current.  The discovery that opposite 
responses occur in response to M1R stimulation depending on Cavβ expression indicates 
a previously unrecognized mechanism of localized control of calcium influx.  
At the cellular level Ca2+ influx through N-channels plays a key role in regulation 
of neuronal excitability, intracellular biochemical processes, and synaptic transmission. 
My findings predict the expression and localization of different CaVβ subunits could 
result in either up- or down-regulating these processes. I’ve shown the coexpression of 
multiple CaVβ subunits in produces a heterogeneous population of channels allowing for 
inhibition and enhancement presumably in different regions of the channel.  For the 
expression of CaVβ not only determines the modulation of the channel, but also the 
localization.   In Madin Darby Canine Kidney (MDCK) cells, a polarized epithelial cell 
line, coexpression of Cav2.1 with CaVβ1b and CaVβ4 resulted in transport of channels to 
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the apical membrane, while CaVβ2a resulted in transport of channels to the basolateral 
membrane (Brice and Dolphin, 1999).  Thus CaVβ2a determines how the channels 
respond to cues for subcellular migration as well as modulation.  
My discovery predicts changes in the expression CaVβ isoforms over time would 
alter N-current modulation in response to M1R stimulation and thus may represent a 
previously unrecognized form of plasticity.  Accordingly, the expression pattern of CaVβ 
subunits associated with N-channels changes during rat brain development (McEnery et 
al 1998).  Also, the distribution of CaVβ isoforms changes in the hippocampi of patients 
with temporal lobe epilepsy (Lie et al 1999), suggesting changes in CaVβ expression may 
be activity dependent.   
The control of M1 moduation by CaVβ subunits may be a general mechanism by 
which numerous Gq coupled receptors (GqPCRs) either enhance or inhibit current. In 
SCG neurons, stimulation of either neurokinin receptor type I (NK-1Rs) or M1Rs inhibit 
N-current through a signaling pathway which requires Gαq and the downstream 
activation of phopholipase Cβ (Shapiro et al. 1994; Kammermeier et al. 2000), therefore 
the NK-1R would likely stimulate a convergent pathway with the M1R. In HEK-M1 cells 
(see Chapter III) expressing N-channels and NK-1Rs, substance P, the natural ligand for 
NK-1Rs, elicited enhancement when CaVβ2a was expressed and inhibition when CaVβ3 
was expressed (data not published; comm. Tora Mitra-Ganguli).  
I found palmitoylation of CaVβ2a alters the N-channel’s response to M1R 
stimulation. Since palmitoylation and depalmitoylation are known to be dynamic 
processes, modulation of N-current may change over the course of seconds to minutes. 
For example, within neurons reversible palmitoylation processes have already been 
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implicated in controlling ion channel clustering at synapses and in decreasing N-channel 
inactivation (Huang & El-Husseini 2005; Hurley et al. 2000).  Thus dynamic 
palmitoylation of CaVβ2a could alter the channels response to modulation as well. 
The discovery that the palmitoylated N-terminus of CaVβ2a plays a key role in 
modulation lends itself to some speculation as to how it does so.  Given that M1 mediated 
modulation of N-current occurs as a result of PtdIns(4,5)P2 depletion, AA formation or a 
combination of the two effects, the N-terminus of CaVβ2a might interact with 
PtdIns(4,5)P2, AA, or both.  First, it seemed possible that the palmitoyl side chains could 
be interfering with a direct interaction of AA on the α1 subunit of the channel (Fig. 6-2).  
However, since the non-palmitoylated CaVβ2a(C3,4S) does not show complete recovery 
of inhibition it does not seem likely that interference of AA is sufficient to block 
inhibition.  Second, the concentration of cationic residues in the N-terminus could be a 
docking site for PtdIns(4,5)P2 (Fig. 6-3).  Thus within the sixteen amino acids of the 
CaVβ2a N-terminus there are possible interaction sites for both AA and PtdIns(4,5)P2.  
If the N-terminus of CaVβ2a is a focal point control of modulation then it would 
seem that its presence would be sufficient to block inhibition.  However, when I 
expressed the chimera with the CaVβ2a N-terminus on a CaVβ3 subunit inhibition was 
only partially blocked.  This could be due to an improper positioning of the CaVβ2a N-
terminus (Fig. 6-4).  It is possible that the structure of the different CaVβ subunits 
position the N-termini differently such that only the wild-type CaVβ2a places the N-
terminus in the exact location necessary to completely block inhibition. 
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M1 stimulation of PKC 
The impetus for most of the research in this thesis came from an aim of 
determining a physiological means to elicit PKC induced phosphorylation of CaV2.2.  
Such a finding would be an important step in understanding neural function for the 
following reasons: 1) CaV2.2 is a vital component of synaptic transmission; 2) Inhibition 
of CaV2.2 by Gβγ binding, together with the relief of inhibition constitute a putative 
mechanism of short term plasticity (Brody and Yue 2000); 3) Phosphorylation of CaV2.2 
by PKC blocks Gβγ inhibition and Gβγ subunits obstruct PKC phosphorylation for an 
elegant control of CaV2.2 activity (Barrett and Rittenhouse, 2000) 4) Efforts to show 
CaV2.2 phosphorylation as a downstream effect of neurotransmitters had been 
unsuccessful (Bean, 2000); and 5) M1 stimulation enhances synaptic release through PKC 
activation (Costa et al., 1993).  Taken together these data suggest the phosphorylation of 
CaV2.2 as a downstream effect of M1Rs is a likely cellular mechanism for current 
modulation. 
I used a pharmacological strategy to dissect the pathway and presented evidence 
consistent with block of fast pathway inhibition and thus consistent with PKC activation.  
My efforts to block the effect with PKC inhibitors were not initially successful; however, 
I found the block of inhibition as presumably elicited by phorbol esters was also difficult.  
Also, during my research on PKC a competing lab published results indicating, 
the PKC activation elicited by M1Rs does not phosphorylate CaV2.2 at the I-II linker thus 
does not potentiate N-current by relief of Gβγ (Kamatchi et al., 2004).  I found the data 
the authors presented to be convincing. One caveat being the work was done oocytes and 
oocytes may lack the components for a proper recapitulation of a signaling pathway of a 
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mammalian neuron.  Still they showed phosphorylation at the II-II linker of CaV2.3 
which indicates activation of PKC.  It’s interesting that the I-II linker of neither CaV2.3 
nor CaV2.2 was phosphorylated by M1 stimulation, but both were phosphorylated by 
phorbol ester stimulation. Another caveat is that they used CaVβ1b in all of their studies 
and CaVβ isoforms can compete at the I-II linker with Gβγ subunits.  If the CaVβ1b 
subunit did not allow sufficient tonic inhibition by Gβγ, then potentiation by 
phosphorylation would never be apparent. 
It’s highly unlikely the consensus site for PKC phosphorylation site on the I-II 
linker evolved without a functional significance. Doubtless there is some mechanism to 
activate a kinase and block Gβγ inhibition.  In addition to oxo-M I tried several other 
agonists for GqPCRs that might activate PKC, including bradykinin, substance P and 
angiotensin II.  But, I was never able to show loss of tonic inhibition with any of these 
ligands which would indicate PKC was not being activated. 
 
Future directions 
In my opinion the most striking discovery I’ve made is the control of modulation 
by CaVβ subunits.  This finding leads to numerous questions and research possibilities. 
The block of inhibition by CaVβ2a provides a molecular tool to probe the enhancing 
effects of AA and GqPCR stimulation.  Interestingly neither AA nor M1 stimulation 
enhances L-type channels (CaV1). This provides an opportunity to create chimeric α1 
subunits to determine which regions of CaV2.2 promote enhancement of current.  Our lab 
has already gathered data indicating L-type channels associated with CaVβ2a have a 
unique response to modulation by AA (unpublished data comm. Mandy Roberts-
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Crowley) but are not enhanced.  In order to ascertain a site of enhancement it would also 
be interesting to see if selective enhancement with CaVβ2a subunits occurs with CaV2.1 
and CaV2.3.  
I suggested that the cationic region of the CaVβ2a N-terminus could act as a 
PtdIns(4,5)P2 binding pocket (Chapter III).  I’d be very interested in how the cationic 
region of the CaVβ2a affects modulation.  Point mutations of the arginine residues near 
the N-terminus might show a loss of the bock of inhibition.  However, it’s not a straight-
forward experiment; mutations could disrupt the consensus site for palmitoylation. 
To really get at how these subunits are affecting modulation it would be best to 
get single-channel recordings of recombinant channels.  The single channel recordings 
would allow one to assess how modulation affects such parameters as mean open time, 
steady state inactivation.  
 
 
162 
Figure 6-1. A Model for M1 Modulation of N-current. As shown M1R stimulation elicits 
PtdIns(4,5)P2 depletion and AA formation, both of which have been shown to cause 
modulation of N-current.  Since N-current seems to be sensitive to both effects, 
experimental conditions involving exogenous application of either PtdIns(4,5)P2 or AA 
could respectively block or elicit N-current modulation. At the present time it is 
impossible to ascertain what the actual concentrations of PtdIns(4,5)P2 or AA are at the 
channel, or to what degree the concentrations fluctuate during M1R stimulation.    
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Figure 6-2. Palmitoylation of CaVβ2a may interfere with direct effect of arachidonic acid 
on channel.  Here is depicted a model by which CaVβ2a might block inhibition by 
causing steric hindrance to AA.  With non-palmitoylated wild-type CaVβ subunits as 
show in (a) AA might directly bind to the α1 subunit causing inhibition.  The palmitoyl 
side chains of CaVβ2a as show in (b) could conceivably block a direct effect of AA. 
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Figure 6-3. CaVβ2a may act as PtdIns(4,5)P2 docking site. (a) depiction of a widely 
accepted model of N-channel inhibition by PtdIns(4,5)P2 depletion.  In this model M1Rs 
couple to PLC through Gαq.  The stimulation of PLC causes a hydrolysis of 
PtdIns(4,5)P2 and resultant concentration gradient within the membrane results in 
PtdIns(4,5)P2 dissociating and diffusing away from the channel.  (b) The N-terminus of 
CaVβ2a contains a concentration of cationic residues which could serve to tether 
PtdIns(4,5)P2 at the channel. Thus as shown in (c) the wild type CaVβ2a would keep 
PtdIns(4,5)P2 from dissociating and diffusing from the channel even if a concentration 
gradient had been formed by PtdIns(4,5)P2 depletion.   
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Figure 6-4. CaVβ2a Sequence may uniquely position N-terminus to block inhibition.  The 
evidence obtained with the chimeric channels indicates that palmitoylation by itself does 
not block inhibition elicited by oxo-M or AA  however we cannot discount the docking 
site hypothesis based on this evidence.  The sequence of amino acids in the CaVβ2a 
isoform may be uniquely adapted to position the N-terminus such that it blocks the effect 
of inhibition.  So as depicted in (a) the wild type CaVβ2a would have the N-terminus 
positioned properly to block inhibition, whereas a chimeric CaVβ subunit as shown in (b) 
could have the N-terminus in an unfavorable position. 
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